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CHAPTER I 
Introduction 
Motivation 
Cardiovascular diseases (CVDs) encompass a wide range of disorders affecting 
the heart and blood vessels. CVDs are widely prevalent in all societies, particularly 
western societies, and the costs associated with the treatment of these diseases continue to 
climb; in the United States alone, the treatment of nearly fourteen million patients costs 
nearly half a trillion dollars per annum [1]. These conditions include angina, arrhythmias, 
atherosclerosis, cardiomyopathy, stroke, hypertension, myocarditis and pericarditis, but 
the most serious cardiovascular disease is coronary artery disease (CAD), a narrowing of 
the blood vessels supplying blood and oxygen to the heart stemming from plaque buildup 
in atherosclerosis, that is responsible for about one sixth of deaths in the United States 
[2]. Atherosclerosis involves a hardening of the arteries over time due to the buildup of 
plaques consisting of fat, cholesterol, macrophages and other substances in blood vessel 
walls. Atherosclerosis typically affects the medium-sized arteries throughout the heart, 
neck, brain and kidneys; however, it can also be found in the aorta [3]. It occurs most 
frequently in areas of turbulent blood flow that occurs near branching points on the
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arteries. Figure 1.1 shows the progression of plaque formation leading to clot formation 
[4].  
Vascular-targeted drug delivery may provide more effective and efficient 
treatment in the intervention of these diseases by providing effective imaging and 
localized drug delivery of potent therapeutics. Vascular-targeted imaging may help to 
identify early atherosclerosis and the associated plaques vulnerable to rupture while drug-
loaded particles targeted to the vasculature may reduce deleterious side effects and more 
effective intervention through the local release of therapeutics. 
Many of the deaths of CAD patients stem from thrombi that form rapidly and 
occlude blood vessels due to the rupture of atherosclerotic plaque. The treatment of CAD 
thus largely occurs after rupture and disruption of vital blood flows associated with tissue 
damage. Surgical intervention is required at the affected site; this reactive treatment is 
invasive and cannot prevent reoccurrence. Preventive treatment largely consists of oral 
application of statin drugs to reduce systemic low-density lipoprotein (LDL) cholesterol 
levels by the inhibition of the enzyme HMG-CoA reductase, which is involved in the 
cholesterol production in the liver. Oral administration of statins is effective at reducing 
acute coronary events stemming from atherosclerosis, particularly in decreasing mortality 
among patients with preexisting CAD; however, acute complications can still occur in 
more than half of patients and treatment is associated with side effects such as raised liver 
enzyme levels and muscle problems [5, 6]. Additionally, statin treatment is much less 
effective in primary prevention, resulting in no significant difference in mortality when
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used in patients with no prior CAD [7]. Since 50%-70% of patients still experience acute 
coronary complications while on statin drugs, there remains a need for more effective 
treatment [6].  
Identification of vulnerable plaque by traditional imaging methods such as X-ray 
angiography and intravascular ultrasound can be difficult since it is often the case that 
plaques that rupture cause less than half luminal narrowing and are thus non-stenotic [8-
12]. Visual differentiation between vulnerable and non-vulnerable plaque is not practical 
via these traditional methods and requires more sophisticated imaging systems. The 
development of imaging methods for early detection and subsequent treatment of 
vulnerable plaques is necessary for improved treatment of cardiovascular diseases. Drug 
carrier systems targeted to the vasculature may provide a means to identify and 
effectively treat such diseased tissues, eliminating the need for invasive surgical 
interventions.  
Plaque formation and destabilization that lead to rupture are preceded by 
physiochemical changes in the tissue. Identification of the presence of proteins associated 
with these biological processes may allow doctors to discern which vulnerable non-
stenotic plaques are in danger of rupture, thus permitting preventive treatment of the 
underlying plaque destabilization causes. Molecular imaging utilizes these proteins 
associated with vulnerable plaque to detect early stage atherosclerosis, such as the 
activity of matrix metalloproteinases involved in plaque destabilization [13-15]. 
Treatment can be localized to the plaques exhibiting such protein activity through the 
active targeting of the proteins themselves, allowing specific plaque treatment and 
increasing effectiveness while reducing adverse side effects [16]. 
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Vascular targets 
Targeted drug delivery carriers fall into two categories – passive and active 
targeting. Passive targeting utilizes particle characteristics (eg. size or shape) in order to 
find the endothelial target from flow, most typically using nanoparticles to pass through 
the leaky endothelium that exists in the vasculature surrounding tumors [17, 18]. Active 
targeting allows for greater specificity of treatment and consists of the attachment of 
ligands to the carrier surface that is specific to a protein uniquely expressed on the 
endothelial surface during the disease state [19-22]. The endothelial monolayer lines the 
lumen of blood vessels throughout the body, serving as a barrier to selectively control 
which materials pass between the blood and surrounding tissue. The endothelium plays a 
vital role in the regulation of several biological processes including the clotting cascade, 
angiogenesis and inflammation.  
Inflammation is the normal process by which the body responds to tissue damage 
or infection; it involves the recruitment of leukocytes from the bloodstream to the site of 
injury where they eliminate the source of inflammation. The leukocyte adhesion cascade, 
outlined in Figure 1.2, is the mechanism by which leukocytes adhere to the endothelium 
and work their way to site of damage [23]. White blood cells are recruited to the site of 
injury through a cascade comprised of distinct steps: initial transient adhesion (rolling), 
firm adhesion, diapedesis and migration into the tissue along a chemotactic gradient [24]. 
Rolling adhesion involves the interaction of endothelial-expressed E- and P-selectins with 
their corresponding carbohydrate ligands on the leukocytes such as sialyl-Lewisx (sLex) 
[25]. P-selectin is rapidly expressed in response to acute inflammation, while E-selectin is 
expressed during chronic, or prolonged, inflammation. Leukocytes are activated during 
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rolling adhesion by cytokines released from the endothelium, leading to firm arrest which 
occurs through activated integrins on the leukocyte binding to intercellular and vascular 
cell adhesion molecules (I- and V-CAM-1) on the endothelial cells [26]. Once firmly 
adherent, leukocytes migrate through the endothelium and underlying tissue to the site of 
injury.  
Inflammation is a normal, necessary body response to injury, but under certain 
conditions a disruption of the shut-off mechanism can lead to the continuous expression 
of inflammation molecules on the endothelium and the corresponding recruitment of 
leukocytes. This chronic inflammation leads to the pathogenesis of several diseases, 
including atherosclerosis [27]. The specific set of protein markers on the endothelium 
responsible for the recruitment of white cells during chronic inflammation may be of use 
for drug delivery. In particular, markers exhibited on endothelial cell surfaces during 
chronic inflammation can be utilized as targets in the imaging and treatment of several 
diseases due to the selectivity of markers and access to the tissue [28]. Drug carriers that 
could mimic this behavior of leukocytes in the recruitment to chronically inflamed 
endothelium might be made by coating their surfaces with ligands specific to chronic 
inflammation. Such vascular targeting has been examined for several types of 
cardiovascular inflammatory diseases where chronic inflammation is present [29-34].  
The major stages of atherosclerosis include plaque initiation, growth and rupture 
and chronic inflammation is expressed on the vascular endothelium at each stage of 
atherosclerosis, causing it to be classified as an inflammatory disease [35]. Plaque 
initiation is associated with the accumulation of LDL cholesterol in the intima of the 
artery, causing chemical changes in the intima and resulting in the upregulation of 
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adhesion molecules on the endothelium (inflammation). This chronic inflammation 
triggers the adhesion cascade of leukocyte, monocytes and T-cells to the vessel intima 
where monocytes differentiate into macrophages, ingest LDL cholesterol and change into 
foam cells [36]. Plaque growth is marked by the migration of basal smooth muscle cells 
(SMCs) into the vessel intima where they form a protective fibrous cap over the lipid 
core. This protective cap is weakened by inflammatory molecule secreted by entrapped 
foam cells in the intima, reducing the SMC and increasing the recruitment of leukocytes 
and, finally, resulting in the plaque rupture.   
Chronic inflammation is expressed on the vascular endothelium at each stage of 
atherosclerosis, making these endothelium-expressed molecules such as the selectins, the 
leukocyte adhesion molecules ICAM-1 and VCAM-1, as well as vascular endothelial 
growth factor viable targets for drug delivery [29-34]. Targeting the selectins is attractive 
due to their very specific and well-understood expression in inflammation. Literature has 
shown the ability of microspheres decorated with selectin antibodies to recognize 
inflammation [37].  
Fibrin clots formed on the atherosclerotic plaques when blood contacts exposed 
tissue offer another means of targeting [38]. Other cells recruited into atherosclerotic 
plaques such as monocytes, T-cells, and foam cells as well as materials including lipids, 
proteases and myeloperoxidase may also be considered as targets (Figure 1.3) [16]. The 
presence of inflammation during atherosclerosis also provides a possible approach to 
therapeutic intervention through localized delivery of anti-inflammatory drugs. For 
example, animal models of atherosclerosis (ApoE- or LDLR-deficient) with added 
deficiency in P- or E-selectin, I- or VCAM-1 have reduced plaque formation [39]. 
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Additionally, there is evidence that the benefit to statin treatment is partially due to their 
anti-inflammatory activity in addition to lowering cholesterol levels [40, 41]. 
Vascular-targeted drug delivery may offer better treatment of CAD, utilizing 
highly potent therapeutics delivered at minimal system drug dosages due to the precise 
targeting to the site of disease. This could provide a non-surgical alternate with an 
opportunity for preventative treatment more effective than systemic statin therapy and 
without its deleterious side effects. Several benefits to such therapy include decreased 
health care costs due to smaller drug dosages and surgeries required, as well as decreased 
mortality rates and improved quality of life for patients with CAD and other chronic 
inflammatory diseases.  
Vascular-targeted drug carrier design 
The design of drug carriers for vascular-targeting must account for several factors 
from particle material and size to targeting ligand attachment. In all cases, the goal of the 
drug delivery system is to arrive at the intended target intact and facilitate the appropriate 
release of therapeutic. Accordingly, there are three major capabilities required from any 
designed system: (1) efficient encapsulation of therapeutics, (2) efficient localization and 
binding to the intended site with protection of loaded cargo and (3) suitable, effective 
drug release once in place. The efficiency of drug carrier localization to diseased tissue is 
paramount, particularly for highly potent therapeutics that may cause adverse side effects 
in systemic circulation. Carriers must navigate through the dense cell population in the 
bloodstream to the cell-free layer near the endothelial wall, avoiding immune clearance 
along the way, and attach to the endothelium at the appropriate location. Blood 
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hemodynamics and the natural immune system clearance of foreign particles tend to 
decrease the circulation time and decrease successful interactions with the vascular wall. 
Drug carriers must avoid rapid immune clearance in order to increase blood 
circulation time and consequent binding efficiency to the endothelium. Synthesizing 
vectors that can avoid immune clearance is a challenge as foreign particles are rapidly 
removed from blood circulation. One approach often utilized is the modification of the 
carrier surface through the addition of ligands, such as PEG, that mask the particles from 
immune clearance [42, 43]. 
Design considerations that impact the effectiveness of these drug vectors include 
the fabrication material, particle size and shape, and modification of particle surface with 
ligands both for targeting and increasing blood circulation times. Biocompatible materials 
must be utilized in the formation of drug carriers such that vectors do not trigger immune 
cascades in the bloodstream, adversely affect contacted blood components and must be 
ultimately removable through degradation by the body. Vectors for drug delivery have 
utilized several classes of materials including soluble proteins, viruses, lipids, inorganic 
molecules and polymers (Figure 1.4) [44]. Each type of particle has its own advantages 
and drawbacks for drug loading, drug release, interaction with blood components and 
ultimate fate within the body. 
Soluble carriers include several classes of small molecules including antibodies, 
biopolymers such as chitosan and dextran, and modified plasma proteins. For example, 
albumin has been conjugated to therapeutics or contrast agents such as gadolinium for 
use with MRI [45]. Soluble carriers are desirable for their ability to exit the bloodstream 
and enter the surrounding tissues, yet they are limited in their loading capacity and 
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require covalent linkage to therapeutics, possibly altering drug efficiency and exposing 
bound therapeutics directly to the bloodstream. Therefore, their use may be limited to 
gene delivery or imaging applications. 
Altered viral particles are attractive as drug delivery carriers in their natural 
ability to avoid clearance from the bloodstream, their innate targeting ability and in that 
they can enter cells. Viruses such as the cowpea mosaic virus have potential for use in 
vascular targeting due to their specific binding to vimentin, which is present on the 
endothelium during the neovascularization of the vasa vasorum in atherosclerosis, and 
have been shown to bind to inflamed endothelial cells [46-48]. The addition of secondary 
molecules has been explored as well to permit their use for other targets [49]. Viral drug 
carriers require complex design due to the need for genetic engineering and growth in 
bioreactors in order for them to gain desired functionality and reduce potential toxicity. 
Lipid-based vectors including liposomes, lipoproteins and micelles have been 
widely proposed as drug delivery and imaging carriers. Liposomes are attractive in their 
ease of fabrication, low toxicity and versatility in the wide range of therapeutics that can 
be loaded into them. Contrast agents can be incorporated into the liposome; for example 
perfluorocarbons have been entrapped within the core of a lipid shell containing 
gadolinium for imaging. This paramagnetic nanoemulsion was used for the MRI imaging 
of atherosclerotic plaques; a similar nanoemulsion has been utilized for ultrasound-based 
molecular imaging [15, 50, 51]. A disadvantage to liquid nanoemulsions is the 
incompressibility of the liquid core, which requires a large concentration of the emulsion 
in order to produce the required image contrast. Gas-filled cores are more echogenic due 
to their compressibility which may mitigate this issue. Indeed, gas- and liquid-filled 
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liposomes have been utilized in ultrasound-based imaging targeting adhesion molecules 
and fibrin [52, 53]. Additionally, ultrasound may be used to trigger the release of 
entrapped agents from echogenic liposomes, allowing their use in targeted drug delivery 
in image-guided therapy [54-56]. Lipoproteins and micelles are limited to hydrophobic 
drugs and their drug loading is difficult relative to other materials. Synthetic high density 
lipoproteins (HDL) may be decorated with contrast agents such as gadolinium and 
targeted to HDL receptors, for example on macrophages entrapped in plaques [57]. 
Additionally, iron oxide can be entrapped within an HDL core for use with MRI imaging 
[58]. Micelles include multifunctional complexes with polymers with the attachment of 
targeting ligands or contrast agents for imaging [38]. 
Several inorganic materials have been fashioned into particles for drug delivery 
including gold, silver, silicon, carbon and iron oxides. For example, iron oxide particles 
coated with polymer have been explored for MRI imaging of cardiovascular systems [59, 
60]. These particles are potentially imaged via both magnetic resonance and x-ray, 
allowing for the overlapping of images and providing detailed information about the 
tissue. Achieving desired loading and release profiles from these particles is difficult, 
however, requiring the tuning of fabricated pore sizes to achieve the desired release 
profile. 
Polymer particles including solid matrix particles, polymersomes and dendrimers 
have been widely proposed for targeted drug delivery due to their flexibility in materials, 
particle size and particle shape. Several biodegradable polymers have been utilized to this 
end, including poly(lactide), poly(glycolide), their copolymer poly(lactide-co-glycolide), 
poly(caprolactone) and poly(ethylene glycol). Polymersomes are made from amphipathic 
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polymers with polar and non-polar ends like the structure of liposomes. They are 
attractive as they maintain membrane flexibility like liposomes, yet they maintain their 
membrane integrity. Dendrimers are tiny polymers branched outwards in successive 
generations that have been proposed as targeted drug delivery and imaging carriers [45, 
61]. Dendrimers have the drawbacks of low loading capacity and toxicity when used in 
high concentrations; therefore may be only suited for gene delivery or imaging 
applications [62-64].  
Solid matrix polymer particles are perhaps the most versatile of carriers due to 
their flexibility in particle size and shape, as well as available biodegradable polymers. 
The surface of these particles can be decorated with a wide variety of targeting ligands 
and contrast agents with large loading capacities for therapeutics incorporated into the 
matrix [65]. One disadvantage to some of these biodegradable polymers is the acidic 
environment they create upon degradation that may damage loaded drug; however, this 
acidic environment may be improved with the co-encapsulation of trehalose or poorly 
soluble bases [66-68]. Overall, particles made from biodegradable polymers seem to offer 
the most flexibility in size and shape, as well as loadable therapeutics and contrast agents.  
 A case for non-spherical particles 
Spherical particles made from biodegradable polymers ranging in size from the 
nanometer to micron size range have been proposed as drug carriers due to their ease of 
fabrication [69-75]. Increasingly, however, there is evidence that spherical carriers may 
not be efficient at targeting the blood vessel wall and that non-spherical particles may be 
more effective as targeted drug delivery carriers. Limited works in literature address the 
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role of particle size and shape on the effectiveness of carrier localization to the vessel 
wall from blood flow.  
Nanospheres are attractive as carriers due to the likelihood that they will avoid 
immune clearance compared to micron-sized carriers. However, recent literature has 
shown that nanospheres display minimal margination (localization and binding) 
compared to micron-sized spheres to endothelial cells from blood flows representative of 
medium to large blood vessels relevant in atherosclerosis (Figure1.5) [76, 77]. This may 
be due to the fact that spheres smaller than two microns have difficulty navigating to the 
vessel wall because of their interactions with red blood cells while larger particles might 
be excluded to a red blood cell-free layer near the vessel wall (Figure 1.6) [72, 77, 78]. 
On the other hand, microspheres are readily internalized by macrophages and cleared 
from circulation [79]. Additionally, the smaller human capillaries are on the order of five 
microns in diameter; occlusion of these vessels by rigid particles may render larger 
microspheres impractical for use as drug delivery carriers.  
Since nanospheres are inefficient at marginating to the vessel wall in blood flow 
and microspheres are readily cleared, there is a need for deviation from spherical shape in 
the design of optimum drug carriers. Non-spherical geometries may provide advantages 
in immune clearance and margination to the endothelium. Macrophages quickly 
internalize spheres up to fifteen microns in diameter, yet are unable to phagocytose 
prolate spheroids when attacking along the major axis of the rod [80]. Long, worm-like 
spheroids were shown to be internalized up to twenty times less by macrophages than 
spheres of the same volume [81]. In vivo studies have also shown benefits of non-
spherical particles in avoiding immune clearance; disk-shaped carriers showed 
 13 
 
significantly increased blood circulation in mice over spheres that were rapidly cleared 
[82]. Cylindrical filomicelle rods persisted in the blood circulation of mice and rats for up 
to a week, more than ten times longer than spheres even when the spheres were 
PEGylated to increase circulation time [83].  
Non-spherical particles also may show improved margination, and thus drug 
delivery efficiency, than their spherical counterparts. Theoretical models of particle 
motion in shear flow near the vessel wall predict prolate spheroids experience a drift 
toward the wall that is absent for spheres due to the hydrodynamic forces and torques 
acting on the rods, suggesting spheroids posses a higher likelihood of reaching the 
vascular wall [84]. Another model predicted that discs would show increased margination 
over spheres [85]. In vitro experiments utilizing simple buffer flow have confirmed these 
models – prolate spheroid and disc shaped particles showed increased margination 
compared to spheres of the same volume [86-88]. Additionally, non-spherical particles 
possess larger surface area than spheres of the same volume, permitting for the 
attachment of more ligands on the particle surface. This increased surface-to-volume of 
non-spherical particles leads to a reduced profile in shear; the particles will likely align 
with flow to expose the smallest cross section to the drag force caused by shearing flow. 
A smaller cross section corresponds to reduced drag force working to pry an attached 
particle off of the endothelial surface. The combination of additional ligand-receptor 
bonds and reduced profile in high shear flows result in a greater adhesive strength of non-
spherical particles to the vascular wall and a decreased likelihood of particle removal 
once bound [89]. Therefore, non-spherical carriers for localized drug or gene delivery 
may lead to enhanced in vivo efficacy of these treatments. 
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Current methods for non-spherical polymer particle fabrication 
Increasing interest in utilizing non-spherical particles as injectable drug carriers 
highlights a need for practical methods of fabricating such particles from biocompatible 
polymers efficiently loaded with a wide range of therapeutics. A number of methods have 
recently emerged in the literature for fabricating non-spherical particles, each with 
advantages and drawbacks. One method involves the stretching of prefabricated spheres 
within a polymer film, requiring monodisperse feedstock spheres, but producing equally 
monodisperse particles in several possible non-spherical shapes [90]. However, the heat 
or solvent required to soften precursor spheres may lead to leaching or degradation of 
loaded therapeutics and the stretching procedure is not easily scalable. Template-based 
methods, including imprint lithography and hydrogel templates, offer great flexibility in 
particle shape; however, these methods are complex in setup and require exposure to 
solvents to separate particles from their molds, possibly leaching their loads [91, 92]. 
Electrohydrodynamic co-spinning can create polymer cylinders with several 
compartments, permitting the utilization of multiple drugs, polymers and even surface 
ligands [93]. Nevertheless, this method is complex in setup and produces long fibers that 
must be sectioned cryogenically, using intense sonication and washing to separate the 
particles, possibly leaking drug loads. The sectioning process is also limited in the 
dimension of each cut, constraining produced particle length to the order of a few 
microns. Microfluidic devices generate monodisperse non-spherical particles, but are 
difficult to scale up and as yet have not shown the ability to load a variety therapeutics 
[94, 95]. 
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There is a clear need for a method to fabricate non-spherical drug carriers from 
biodegradable polymers that is simple in setup and operation to allow for quick access to 
prolate spheroid particles. Additionally, the fabrication method needs to be adaptable to a 
wide variety of biodegradable polymers and therapeutics, as well as allowing the efficient 
attachment of ligands for targeting and avoiding blood clearance. Oil-in-water emulsion 
solvent evaporation (O/W ESE) fabrication techniques are advantageous in their 
inexpensive, simple setup and operation, have been reported for a wide range of 
therapeutics and biodegradable polymers, are easy to scale up (yielding a sufficient 
particle mass), and provide favorable surface characteristics for ligand attachment [96-
98]. Utilizing knowledge of droplet deformation in such mechanically mixed emulsions, 
it was possible to utilize this technique to fabricate prolate spheroids from biodegradable 
poly(lactic-co-glycolic acid) (PLGA) polymers. Specifically, manipulation of droplet 
dynamics and the diffusion process during the emulsification and solidification phases of 
particle formation was used to form stretched particles for use in drug delivery 
applications. 
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Figure 1.1: Normal and atherosclerotic arteries: deposits of plaque accumulate at the site 
of injury on the inner lining of the artery due to uncontrolled chronic inflammation at that 
site. As these plaques grow and harden, they may occlude blood flow or break off and 
cause a clot leading to infarct, stroke or embolism [4].  
 
 17 
 
 
 
 
 
Figure 1.2: The leukocyte adhesion cascade showing the natural inflammation response 
to tissue damage. Proteins specific to inflammation such as the selectins and ICAM-1 
decorate the surface of the endothelium near the site of injury, capturing passing 
leukocytes from the bloodstream and directing them into the tissue [23]. 
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Figure 1.3: Potential targets in atherosclerotic plaque lesions for imaging or delivery of 
therapeutic treatments. Targets include chronic inflammatory proteins on the endothelial 
surface, clotting agents on exposed plaque and cells and other components within the 
fibrous cap itself [16]. 
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Figure 1.4: Soluble, polymer- and lipid-based particles proposed for use as drug delivery 
or imaging carriers [44].  
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Figure 1.5: Adhesion of spherical polymer particles targeted to inflamed endothelial cells 
from blood flow in a parallel plate flow chamber [76].  
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Figure 1.6: Margination of nanospheres and microspheres to the endothelium from bulk 
blood flow in medium-to-large blood vessels. Adapted from Huang et. al. [72].
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CHAPTER II 
A novel fabrication of prolate spheroids from biodegradable polymers 
via the oil-in-water emulsion solvent evaporation method 
Introduction 
Oil-in-water emulsion solvent evaporation techniques employ mechanical mixing 
to create an emulsion consisting of oil droplets (the dispersed phase) within an aqueous 
phase (the continuous phase) in the presence of an emulsifying agent that stabilizes 
formed droplets. The shear forces imparted by the impeller cause the dispersion of the oil 
phase into droplets coated with the surfactant at the interface between the phases. Within 
O/W emulsions, the oil phase contains polymer that the particles will be formed from 
along with therapeutics to be encapsulated dissolved in an organic solvent that has 
limited solubility in water. The aqueous phase contains the emulsifier, often a surface 
active agent (surfactant) that coats the oil droplets, providing thermodynamic stability.  
Particle formation in mechanically mixed emulsions can be divided into three 
stages: (1) droplet formation (emulsification), (2) solvent removal (solidification) and (3) 
drying. The solvent removal, or solidification, stage is the critical stage for
controlling particle size and shape within such emulsions and can be further broken down 
into three states: (i) solvent, (ii) gel and (iii) glass. In the emulsification, or droplet 
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formation, stage, the mechanical shear forces disperse the oil phase into droplets that 
break into smaller droplets and coalesce into larger droplets as they bump into each other, 
eventually reaching an equilibrium and characteristic size for the emulsion. The 
solidification stage involves the diffusion of the organic solvent, which is often volatile, 
into the surrounding aqueous phase. During the solvent removal stage, the oil droplet is in 
either a solvent, gel or glass state. In the solvent state, the oil droplet largely consists of 
the organic solvent with dissolved polymer and drug. The solvent diffuses from the oil 
phase into the continuous phase, leaving the polymer behind; after a significant portion of 
the solvent has diffused into the continuous phase, the polymer-rich oil phase is in a 
deformable, semisolid state containing a mix of polymer and solvent. Once enough 
solvent has diffused out of the droplet, the remaining polymer is in a glass state that can 
no longer change in size or shape. Removal of any residual solvent in the newly formed 
polymer particle occurs in the drying stage.  
Deformation and/or breakup of the droplets from a spherical shape into a 
stretched spheroid or smaller sphere occur depending on the conditions of the 
mechanically stirred emulsion. The continuous and oil phases can be manipulated such 
that high-shear stirring during the solvent and gel states of solvent removal causes 
deformation of the oil droplets from spheres to prolate spheroids that remain as solvent 
diffusion solidifies the particles into glass states that retain their stretched character and 
will not relax into spheres. The deformation and breakup of the oil droplets can be 
characterized by two dimensionless numbers: (1) the viscosity ratio, a ratio of the droplet 
phase viscosity to that of the continuous phase: 
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  Eqn. (2.1) 
where ηd is the droplet phase viscosity and ηs is the continuous phase viscosity, 
and (2) the capillary number, a ratio of viscous forces pulling the droplet apart to 
capillary forces holding the droplet together: 


a
Ca s

 Eqn. (2.2) 
where γ is the shear rate, ηs is the viscosity of the continuous phase, a is the 
droplet size and Γ is the interfacial tension between the droplet and the continuous phases 
[1]. Typically, a low viscosity ratio and high capillary number (high viscous forces or low 
interfacial tension forces) result in conditions that favor droplet deformation. Low 
viscosity ratios (M«1) favor large droplet deformation (large aspect ratios) before 
breakup, intermediate viscosity ratios (M~1) lead to less deformation prior to breakup 
and high viscosity ratios (M>4) allow for minimal droplet deformation and breakup. 
Increasing the capillary number results in increased deformation up to the point of droplet 
breakup at the critical capillary number for a given viscosity ratio [1].  
Prolate spheroids can be produced using this O/W ESE for a certain range of 
viscosity ratios and capillary numbers. If the right conditions exist during the 
emulsification and solidification stages, oil droplets stretched by the viscous shear forces 
will facilitate faster diffusion of the organic solvent into the continuous phase, solidify 
the droplets faster and lock them in a stretched conformation. Spheroids (unloaded and 
drug loaded) can be fabricated at a high rate of up to 10
9
 particles per hour (per 50 mg 
batch of PLGA polymer) using the O/W ESE through the manipulation of the viscosity 
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ratio and capillary number via variation of components the aqueous and oil phases as well 
as the physical setup of the system. 
Aqueous phase parameters varied included surfactant (polyvinyl alcohol) 
concentration, the addition of tris(hydroxymethyl)aminomethane (tris) to reduce 
interfacial tension and the aqueous phase pH through the addition of hydrochloric acid or 
sodium hydroxide. The physical setup of the system was modified by varying mechanical 
stir rate and oil-to-aqueous phase volume ratio. For all experiments, the reactor vessel, 
temperature, agitator diameter and position, and the reaction volume remained constant. 
Several characteristics of the oil phase were varied including the addition of co-solvents, 
the concentration of dissolved polymer and PLGA polymer characteristics including 
molecular weight, co-monomer ratio and end group.  
Materials and methods 
Microparticle fabrication 
Microparticles were fabricated from PLGA polymer via the oil-in-water emulsion 
solvent evaporation method as previously described [2, 3] with high surfactant 
concentration and the presence of tris base. PLGA polymer was dissolved in 
dichloromethane to form the oil phase. The relevant characteristics of the different types 
of PLGA polymers utilized are summarized in Table 2.1. The aqueous phase consisted of 
the surfactant polyvinyl alcohol (MW 30,000 – 70,000) with the surface-active molecule 
tris base dissolved in deionized water and maintained at a constant pH via titration with 
either hydrochloric acid or sodium hydroxide. The oil phase containing the polymer was 
injected into the aqueous phase under continuous stirring using a Lightnin’ mixer (model 
L1U08F) fitted with a glass propeller (Beckman Coulter – shaft diameter = 2.8 cm). The 
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resultant mechanically mixed emulsion was stirred for a minimum of one hour in order to 
facilitate solvent removal via evaporation. The resulting microparticles were collected via 
centrifugation at 750 rpm and washed three times with deionized water prior to freeze-
drying in a Labconco lyophilizer. The resultant particulate powder was stored at -20°C 
until use.  
Unless otherwise stated, the following base conditions were present during the 
fabrication process: 50 mg PLGA polymer (polymer A – Table  2.1) were dissolved in 10 
ml dichloromethane to form the oil phase. The aqueous phase consisted of deionized 
water at pH 8.4 (titrated with hydrochloric acid) with 1.0% w/V PVA and 1.2% w/V tris. 
The 10 ml oil phase was injected over thirty seconds into 100 ml of the aqueous phase 
while stirred at 1800 rpm for one hour. This composition permitted the formation of 
stretchable oil droplets and solvent evaporation necessary for droplets to solidify in the 
stretched conformation.  
Microparticle characterization 
The physical characteristics including size and shape of fabricated microparticles 
were studied using a Nikon TE 2000-S optical microscope and a Philips XL30FEG 
scanning electron microscope (SEM). Samples were prepared for light and scanning 
electron microscopy by suspending powdered (freeze-dried) microparticles in deionized 
water and pipetting the suspension onto either a microscope slide or double-sided carbon 
tape affixed to an SEM stub. The particle suspension was air-dried on the SEM stub and 
subsequently gold-coated using a SPI-Module sputter coater prior to analysis via SEM. 
Particle sizes and aspect ratios were obtained from light and scanning electron 
microscopy via Metamorph analysis software. All data is reported as an average of a 
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minimum of three fabrication batches with standard error between batches. Significance 
in data between different process variables was assessed using all data points obtained 
through multiple batches via student’s t-test and one-way Anova with post-test. A p value 
of 0.05 was considered significant. 
Results and Discussion 
Aqueous phase parameters 
Tris(hydroxymethyl)aminomethane (tris base) concentration in the aqueous phase 
Tris(hydroxymethyl)aminomethane is a base often used as a pH buffer, 
particularly in biochemistry due to its buffer range (pH 7-9) coinciding with 
physiological pH [4]. Herein it is used both as a pH buffer and to decrease the interfacial 
tension between the discontinuous and continuous phases. Polyvinyl alcohol was utilized 
as the surfactant in this system in order to stabilize the emulsion; however, without the 
presence of tris base in the aqueous phase, only spheres were produced regardless of 
PVA concentration. A small concentration (0.3% w/V) of tris base considerably reduced 
interfacial tension between the oil and aqueous phases as is shown in Figure 2.1, 
significantly increasing the capillary number for a given viscosity ratio and providing the 
environment needed for droplet deformation. Further addition of tris base up to a 
concentration of 4.0% w/V resulted in a further reduction of interfacial tension; however, 
the effect diminished as tris concentration increased.  
The effect of tris base concentration ranging from 0.3% to 2.0% w/V in the 
aqueous phase on particle size and shape was studied at a constant PVA concentration of 
2.0% w/V. All other process parameters did not vary from the base conditions. Increasing 
tris concentration resulted in decreased droplet deformation (aspect ratio) and spheroid 
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fraction as shown in Figure 2.2; however, particle volume was unchanged. As the 
concentration of tris base increased from 0.3% to 2.0% w/V, the spheroid fraction 
decreased from 90% to 42% and the particle aspect ratio decreased from 7.2 to 3.9. At a 
decreased PVA concentration (1.0% w/V), the spheroid fraction remained high (greater 
than 90%) for greater tris concentrations (up to 1.2% w/V), but still decreased to 60% 
with 2.0% w/V tris base.  
Particles fabricated in the presence of at least 1.0% w/V tris base displayed 
smooth surface characteristics for all PVA concentrations tested while those fabricated in 
low tris base (<1.0% w/V) and high PVA concentrations (>1.2% w/V) aqueous buffers 
displayed a rough surface morphology (Figure 2.3). PVA is the system surfactant that 
provides droplet stability, yet without tris base in the buffer, only spheres were produced 
regardless of PVA concentration. Tris base is not a surfactant, but provides the interfacial 
environment required for droplet deformation to occur through the hydrophilic groups of 
the tris molecule (Figure 2.3) that interact with the hydrophilic end groups of the polymer 
chain in the oil phase to decrease interfacial tension [5]. High concentrations of PVA at a 
given tris base concentration seem to diminish the interfacial effect of tris base, perhaps 
by occupying the interface and crowding out tris, blocking its effect.  
The reduction of droplet deformation with increased tris concentration is likely 
the result of the increased electrolytes due to the increased hydrochloric acid (HCl) 
concentration required to maintain the aqueous buffer pH at 8.4 with increasing tris base. 
Increased electrolytes in the aqueous phase decrease the concentration of PVA at the 
phase interface and decrease the solubility of the oil phase in the water phase [5]. This 
hypothesis was tested through variation of HCl concentration; particles were fabricated at 
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2.0% w/V tris base concentration with no pH adjustment (pH 9.7) and with half HCl 
concentration (pH 9.1). Particle aspect ratio and spheroid fraction increased significantly 
with decreased HCl concentration as shown in Figure 2.4, confirming the hypothesis. 
Aqueous phase pH 
The aqueous phase pH, controlled by the addition of acid or base, is of interest 
due to its influence on the interfacial effect of tris base and its potential impacts on drug 
encapsulation. In order to study the potential effect of aqueous phase pH on the physical 
characteristics of fabricated particles, the aqueous buffer pH was varied between 5.0 and 
10.0 for buffers containing 1.0%, 1.8% and 2.5% w/V PVA concentrations at a fixed tris 
base concentration of 1.2% w/V by the addition of hydrochloric acid. At the most acidic 
pH tested (5.0), no spheroidal particles were formed – only spheres were produced. As 
the aqueous phase pH increased from 5.0 to 8.4, the fraction of produced particles that 
were spheroids increased as shown in Figure 2.5; likewise, the elongation (aspect ratio) 
of the spheroid particles increased significantly for all PVA concentrations examined. 
Further increase in pH beyond 8.4 up to 10.0 did not significantly alter spheroid fraction 
or aspect ratio. 
Spheroidal particles are preferentially produced at basic pH at constant PVA and 
tris concentrations; this is likely due to the effects of decreased interfacial tension (and 
thus increased capillary number) at higher aqueous phase pH, either through tris or PVA. 
Since the pK of tris is about 8.1, buffer pH below this value will result in the lone 
electron pair on the tris base amine group being largely protonated, possibly reducing the 
interaction between tris and the polymer end groups in the oil phase. Additionally, 
polyvinyl alcohol has been shown to have lower interfacial tension at higher pH [6, 7] 
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and the pH of the aqueous phase in emulsion solvent evaporation fabrication techniques 
can impact the loading of therapeutics [8, 9].  
Polyvinyl alcohol concentration in the aqueous phase 
Polyvinyl alcohol is the surfactant used to emulsify the oil phase within the 
aqueous phase, working to stabilize the oil droplets and cause their deformation. 
Additionally, PVA concentration can be used to manipulate the viscosity of the aqueous 
phase such that PVA plays a dual role in this system as both a surfactant and a means to 
influence buffer viscosity. PVA concentrations were varied from 0.3% to 4.0% w/V, 
resulting in an increase in buffer viscosity from 1.1 to 5.5 millipascal-seconds (mPa-s) as 
measured by a Cannon-Fenske viscometer (size 50) and shown in Figure 2.6.  
PVA concentrations between 0.3% and 4% w/V in the aqueous phase were 
examined at constant tris base concentration (1.2% w/V), pH (8.4), stir rate (1800 rpm), 
polymer concentration (5 mg/ml) and oil phase fraction (0.09). As shown in Figure 2.7, 
increasing PVA concentration up to 1.0% w/V resulted in larger droplet deformation 
(aspect ratio) and a larger fraction of spheroids as expected due to the increase in aqueous 
phase viscosity. There was no significant difference in spheroid fraction (>95%) or aspect 
ratio (~7) for PVA concentrations between 1.0% and 2.0% w/V, while further increase in 
PVA beyond 2.0% w/V resulted in a smaller spheroid fraction and reduced aspect ratios 
corresponding to reduced droplet deformation.  
Increasing the concentration of PVA served a dual role through the corresponding 
increase in aqueous phase viscosity and as the system surfactant. First, the high viscosity 
of the continuous aqueous phase slowed the oil solvent removal rate via diffusion, 
allowing the droplet to persist in the gel phase long enough for droplet deformation. 
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Second, an increased continuous phase viscosity directly lowers the viscosity ratio and 
increases the capillary number, favoring droplet deformation and, ultimately, forming 
spheroidal particles. 
This decrease in droplet deformation and fraction spheroids beyond 2.0% w/V 
PVA is due to competing effects of increasing buffer viscosity: (1) increased shear forces 
acting on the oil droplets due to increased viscosity that favor droplet deformation 
through decreased viscosity ratio and increased capillary number and (2) smaller initial 
oil droplet diameters formed during emulsification that resist deformation through a 
decreased capillary number. A critical capillary number exists for a given viscosity ratio 
such that increased viscous forces beyond this results in droplet breakup, producing 
smaller droplets that resist deformation [1]. This decrease in particle volume with PVA 
concentration, a direct result of smaller droplet diameter, is shown in Figure 2.7. The 
consistent aspect ratio and spheroid particle fraction seen between 1.0% and 2.0% w/V 
PVA is due to a balance between these competing effects of decreasing droplet size and 
increasing shearing forces. Beyond 2.0% w/V PVA the smaller droplet size begins to 
dominate and this results in decreased droplet deformation, as observed in the average 
aspect ratio as well as decreased spheroid fraction due to the droplets falling below the 
critical droplet diameter required for stretching at constant interfacial tension. 
Additionally, it is likely that the reduced droplet deformation and low spheroid fraction 
observed at high PVA concentrations is a result of the PVA interfering with the 
interfacial effect of the tris base. PVA acts as a surfactant and although it is necessary for 
droplet stability and stretching, the presence of tris base in the aqueous phase is necessary 
for the fabrication of spheroids. 
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Physical setup parameters 
Mechanical stir speed 
The mechanical stir speed in a stirred emulsion proportionally affects the shear 
rate, increasing the viscous shear forces acting on the oil droplets. The effect of 
mechanical stir speed on particle size and shape was studied at 1200 and 1800 rpm for 
aqueous phases containing 0.3%, 1.0%, 2.5% and 4.0% w/V PVA concentrations and 
base conditions for other process parameters. The volume of fabricated particles 
decreased at the faster stir rate for each PVA concentration as shown in Figure 2.8. In 
general, particle elongation decreased with increasing stir rate. Spheroid fraction 
decreased with increasing stir rate at all PVA concentrations except 1.0% w/V where 
there was no difference in spheroid fraction. Likewise, spheroid aspect ratio decreased 
with increasing stir rate for all PVA concentrations apart from 2.5% w/V where aspect 
ratio was not significantly different.  
The impacts of shear rate on the size of the oil droplets and resultant particles 
have been widely studied in the literature – increasing stir rate results in decreased 
particle size as particle breakup increases with increasing shear [10-13]. In this 
mechanically mixed oil-in-water emulsion solvent evaporation system, however, the 
effects of shear rate on not only droplet size but droplet deformation as well were 
unknown since increased shear increases the capillary number (Eqn. 2.2) and increased 
capillary number results in both increased droplet deformation and droplet breakup, 
which precludes further elongation.  
Droplet breakup due to increased shear forces (and increased capillary number) at 
the higher stir rate was the dominant effect at all PVA concentrations studied. The larger 
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oil droplets produced during initial emulsification at lower stir speeds allowed for greater 
droplet deformation in the solvent removal phase. While stir speeds greater than 1800 
rpm were not studied due to equipment limitations, it is likely that the system would 
move further towards spherical particles due to the larger initial droplet breakup in the 
emulsification phase. 
Oil-to-Aqueous Volume Ratio 
The ratio of oil phase volume to aqueous phase volume has been shown to modify 
the average particle volume in mechanically mixed emulsions due to the increase in 
solution viscosity with increasing droplet phase volumes [14]. The effect of the phase 
volume ratio was studied for oil phase volume fractions between 0.045 and 0.182 on the 
resultant particle shape and size at a constant fabrication volume (sum of the oil and 
aqueous volumes) of 110 ml. An increase in the oil phase volume fraction resulted in a 
corresponding decrease in the particle volume as shown in Figure 2.9. However, droplet 
deformation as measured by fraction spheroids and aspect ratio showed no significant 
difference with increasing oil phase volume fraction. An increase in solution viscosity 
with increasing oil phase fraction leads to greater shear forces on the particles; in the 
range of volume ratios studied, the larger shear forces increasing the capillary number led 
to droplet breakup rather than further droplet deformation, similar to the effect seen with 
increasing PVA concentration and stir speed. 
Oil phase parameters 
PLGA polymer chain end group 
Polymer chains terminate in end groups that have large effects on the 
characteristics of the polymer as a whole [15-17]. Varying polymer end group impacts 
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polymer behavior not only in the fabrication of polymeric particles, but also on their 
characteristics in their application whether in vitro or in vivo; additionally, they offer 
opportunities for the chemical addition to the polymer post particle fabrication, such as 
the addition of ligands for use in targeted drug delivery. PLGA polymer with three 
different end groups: carboxylic acid (PLGA-acid), poly(ethylene-glycol) (PLGA-PEG) 
and ester (PLGA-ester) (polymers A, H and I, respectively, Table 2.1), were utilized to 
study the effects that polymer end group have on fabricated particle size and shape. 
Particles were fabricated at base formulation conditions. Particles fabricated from PLGA-
acid formed nearly all spheroids while those made from PLGA-PEG were mostly spheres 
and particles made from PLGA-ester showed no elongation (Figure 2.10). Formed 
spheroid particle aspect ratios followed accordingly; PLGA-acid particles had an average 
aspect ratio of 7.0 ± 1.0, PLGA-PEG 4.0 ± 0.2 while PLGA-ester showed no elongation.  
Unsurprisingly, the hydrophobic ester end group polymer showed no elongation 
as the increased interfacial tension between the oil and aqueous phases due to the 
increased hydrophobicity of the polymer decreased the capillary number such that shear 
forces could not overcome capillary forces to induce deformation. Increased interfacial 
tension forces in PLGA-ester systems has been previously documented and has shown to 
produce larger particles than PLGA-acid polymer of similar molecular weight due to 
increased capillary forces decreasing droplet breakup [18]. Conversely, the acid end 
groups of PLGA-acid that are hydrophilic in nature interact with tris and PVA in the 
aqueous buffer, lowering the interfacial tension between the phases and favoring droplet 
deformation. The PEG end groups are similarly hydrophilic nature; however, droplet 
breakup dominated in this case, causing reduced elongation compared to PLGA-acid 
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(Figure 2.10). When the stir speed was decreased to 1200 rpm, particles fabricated from 
PLGA-PEG increased in spheroid fraction and aspect ratio due to the larger initial droplet 
diameter (Figure 2.11). Particles fabricated from PLGA-ester remained spherical at 
conditions tested.  
PLGA polymer molecular weight 
The effect of polymer molecular weight on fabricated microparticle 
characteristics was studied at 1.0% w/V PVA with three PLGA polymers varying in 
inherent viscosities and corresponding molecular weights (Polymers B-D, Table 2.1). 
Particle elongation decreased as the polymer molecular weight increased, resulting in a 
smaller fraction of spheroids and lower particle aspect ratios (Figure 2.12).  
Polymer molecular weight is one characteristic of polymers that directly impacts 
oil phase viscosity and has been shown to affect the physical characteristics of fabricated 
particles as well as the drug load [19, 20]. Increasing polymer molecular weight increases 
its chain length, resulting in an increased chain interaction and entanglement. 
Furthermore, longer chains equate to fewer chains for a given mass and results in a lower 
concentration of hydrophilic end groups available to interact with the aqueous phase, 
reducing droplet deformation. The observed experimental results show that increased 
molecular weight decreases droplet deformation due to both increased oil phase viscosity 
and increased interfacial tension. 
PLGA polymer concentration in the oil phase 
Oil phase viscosity is dependent on the concentration of PLGA polymer dissolved 
in the organic solvent. Additionally, polymer concentration in the oil phase has been 
shown to impact particle characteristics as well as drug loading [21]. The effect of 
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increasing PLGA polymer concentrations in the oil phase were studied at the base 
process parameter formulation for 2.5, 5.0 and 10.0 mg/ml PLGA polymer to 
dichloromethane. Polymer concentration was increased by increasing the mass of 
polymer dissolved while maintaining the base formulation volumes of the oil and 
aqueous phases, that is, 10 and 100 ml, respectively. Increasing polymer concentration in 
the oil phase resulted in increasing spheroid fraction and aspect ratios of fabricated 
particles as shown in Figure 2.13, indicating a net increase in droplet deformation with 
increasing polymer concentration over the range examined.  
Increasing oil phase polymer concentration results in further chain entanglement 
and interaction, increasing viscosity and likely lowering droplet deformation. Conversely, 
increasing polymer concentration proportionally increases the number of polymer chain 
end groups available for interaction with the aqueous phase, tending to increase droplet 
deformation. The greater number of hydrophilic end groups decreases interfacial tension 
between the phases, leading to an increase in aspect ratio as droplet deformation 
increases. 
PLGA co-monomer ratio 
The co-monomer ratio is the ratio of lactic to glycolic acid monomers forming the 
backbone of the PLGA chain and is known to affect the physical characteristics of 
fabricated particles, particle degradation and encapsulation efficiency of loaded drugs 
[18, 21]. Particles were fabricated from PLGA polymers containing co-monomer ratios 
ranging from 50 to 85 mol% lactic acid with equivalent molecular weights at the base 
process parameter formulation (polymers A, E, F & G – Table 2.1). As expected due to 
the relatively increased hydrophobic nature of lactic versus glycolic acid, fabricated 
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particles exhibited a decrease in aspect ratio with increasing lactic acid mole fraction 
(Figure 2.14). Additionally, particle size increased significantly with increasing amounts 
of lactic acid in the PLGA backbone as observed previously in literature [21] even though 
there was no appreciable difference in oil phase viscosity. 
Lactic and glycolic acid are similar in structure except that lactic acid has an 
additional methyl side group that causes an increased hydrophobicity in the lactic 
monomer. PLGA polymers with larger fractions of lactic acid in their backbone will 
therefore be more hydrophobic and will cause increased interfacial tension between the 
oil and aqueous phases, likely leading to less droplet deformation. This was observed as 
the particle aspect ratio decreased and particle volume increased with increasing lactic 
acid monomer. 
Oil phase co-solvent: Acetone 
The organic solvent used in the dispersed oil phase impacts the particle size and 
droplet deformation in the oil-in-water emulsion systems. Unloaded PLGA particles were 
fabricated with dichloromethane and acetone as co-solvents in varying ratios while 
keeping all other variables constant, including total oil phase volume (10 ml). As the 
volume fraction acetone increased from 0% to 50% in the oil phase, the aspect ratio of 
fabricated spheroids increased from 7.0 to 11.6 while there was no significant change in 
either fraction spheroids (94% to 92%) or particle volume (205 to 190 µm3) as shown in 
Figure 2.15. No particles were formed at 80% volume fraction acetone, which is 
unsurprising since the solubility of PLGA in acetone is limited. The increased oil phase 
solubility and corresponding diffusion rate into the aqueous phase does not necessarily 
correlate to a change in particle volume; literature has reported a decrease, no change or 
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increase in particle volume with increasing co-solvent volume fractions depending on the 
system studied [22-24]. 
The solubility both of the polymer in the organic solvent it is dissolved in and of 
the solvent in the aqueous phase will determine the speed of solvent removal into the 
water phase. This has implications not only for the resultant particle size, but also for the 
loading efficiency of encapsulated therapeutics. Dichloromethane, the organic solvent 
utilized in this fabrication technique, has low solubility in the aqueous phase, yet is much 
more water-soluble than many other organics, offering relatively fast diffusion compared 
to other organics [25]. Similarly, the addition of water-soluble co-solvent, such as 
methanol or acetone, increases the diffusion between both phases, increasing water 
diffusion into the oil phase as well as solvent diffusion into the aqueous phase.  
Acetone does two things as a co-solvent; it lowers the oil phase viscosity and 
increases the solubility of the oil phase in the water phase. Decreasing the oil phase 
viscosity directly lowers the viscosity ratio, allowing for greater droplet deformation prior 
to breakup and likely resulting in larger aspect ratios. Increased solvent solubility in the 
water phase increases the solvent removal rate and lowers the interfacial tension between 
the two phases, increasing the capillary number and leading to greater stretching. This 
was observed experimentally as the aspect ratio increased with increasing acetone 
volume fraction due to the decreased viscosity ratio and the increased capillary number. 
Polydispersity of fabricated microparticles 
Particles fabricated from oil-in-water emulsion systems are non-uniform in size 
due to the variability of droplet volumes created when the dispersed phase separates into 
individual droplets upon emulsification. Additionally, the deformation of individual 
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droplets, as measured by the aspect ratio of the resultant hardened spheroids, may differ 
due to non-uniform forces of the forced and free vortices caused by the agitator. The 
uniformity of created particles is important for the efficiency of targeted drug delivery; 
some particle volumes and aspect ratios may be more effective at marginating to the 
blood vessel wall from flow than others. Therefore, a monodisperse population of 
particles is desired to ensure the efficiency of targeting and thus the effectiveness of 
overall treatment. The polydispersity of the fabricated particle population can be 
measured by the square of the standard deviation divided by the square of the 
measurement: 
2
2
x
PI

  Eqn. (2.3) 
where σ is the standard deviation in the variable x. A smaller PI indicates a 
smaller spread of values and is therefore desirable. The polydispersity of both volume 
and aspect ratio were examined for particles fabricated using the oil-in-water emulsion 
solvent evaporation technique.  
Figure 2.16 shows the effect of tris base in the aqueous phase on the volume and 
aspect ratio polydispersity indexes for fabricated particles; aspect ratio polydispersity 
increased with increasing tris concentrations. The effects of each fabrication parameter on 
aspect ratio and volume polydispersities are shown in Table 2.2. Aspect ratio 
polydispersity decreased significantly with increasing stir rate, increasing lactic acid co-
monomer fraction, decreasing tris concentration and decreasing pH. Volume 
polydispersity decreased significantly with increasing stir rate, increasing PLGA 
concentration and decreasing tris concentration. Thus, it is possible that a combination of 
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low tris concentrations, high mole fractions of lactic acid co-monomer and fast stir rates 
would result in small aspect ratio polydispersity.  This hypothesis remains to be tested. 
Summary 
This work describes a novel fabrication of non-spherical particles from 
biodegradable PLGA polymer for drug delivery applications utilizing oil-in-water and 
water-in-oil-in-water emulsion solvent evaporation techniques. It was shown that the size 
and shape (aspect ratio) of these fabricated prolate spheroids can be controlled by careful 
manipulation of process parameters in the aqueous and oil phases as well as the physical 
setup of the system. Table 2.3 shows a qualitative summary of the effect each fabrication 
parameter has on the spheroid fraction, aspect ratio and volume of particles fabricated 
using this method. The data showed that moderate aqueous phase viscosities, a basic 
aqueous phase pH, the presence of moderate amounts of tris and hydrophilic end groups 
on the polymer chain are all conditions that promote formation of spheroidal particles. 
High PLGA concentration in the oil phase, hydrophilic end groups, a water soluble co-
solvent (acetone) and basic aqueous phase pH all led to larger aspect ratios. Fast stir 
rates, large oil phase volume fractions, a large mole fraction of glycolic acid co-monomer 
and large aqueous phase viscosity led to a decrease in particle volume. 
 
 
 
 
 
 49 
 
 
 
 
 
 
 
 
Table 2.1: Poly(lactic-co-glycolide) polymers used to fabricate prolate spheroid particles. 
Polymer A was purchased from Birmingham Polymer while all other polymers were 
purchased from Lakeshore Biomaterials. IV = polymer inherent viscosity. 
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Figure 2.1: Interfacial tension between water phases containing varied tris concentrations 
in deionized water and oil phases containing dichloromethane. Measurements were made 
using a Du Noüy ring force tensiometer between 20 ml of each phase.  
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Figure 2.2: (A) Aspect ratio, (B) spheroid fraction and (C) volume of fabricated particles 
as functions of the aqueous phase tris concentration for microparticles fabricated from 
polymer A. PVA concentration = 2.0% w/V. Aqueous phase pH = 8.4. Stir rate = 1800 
rpm.  
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Figure 2.3: (A) Unloaded PLGA particles fabricated from the oil-in-water emulsion 
solvent evaporation method made from polymer A. PVA concentration = 2.0% w/V. Tris 
concentration = 0.3% w/V. Aqueous phase pH = 8.4. Stir rate = 1800 rpm. (B) The 
structure of the tris molecule. 
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Figure 2.4: Aspect ratio of fabricated particles as a function of aqueous phase pH for 
microparticles fabricated from polymer A. PVA concentration = 2.0% w/V. Tris 
concentration = 2.0% w/V. Stir rate = 1800 rpm. Aqueous phase pH 8.4 corresponds to 
0.02 M hydrochloric acid, pH 9.1 corresponds to 0.01 M HCl and pH 9.7 has no acid 
added. 
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Figure 2.5: Spheroid fraction of fabricated particles as a function of aqueous phase pH 
for microparticles fabricated from polymer A. PVA concentration = 1.0, 1.8 or 2.5% 
w/V. Tris concentration = 1.2% w/V. Stir rate = 1800 rpm. 
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Figure 2.6: Kinematic viscosity of the aqueous phase as a function of PVA 
concentration. 
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Figure 2.7: (A) Aspect ratio, (B) spheroid fraction and (C) volume of fabricated particles 
as functions of the aqueous phase PVA concentration for microparticles fabricated from 
polymer A. Tris concentration = 1.2% w/V. Stir rate = 1800 rpm. Aqueous phase pH = 
8.4. 
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Figure 2.8: (A) Aspect ratio, (B) spheroid fraction and (C) volume of fabricated particles 
as functions of the stir rate for microparticles fabricated from polymer A. PVA 
concentration = 0.3, 1.0, 2.5 or 4.0% w/V. Tris concentration = 1.2% w/V. Aqueous 
phase pH = 8.4. 
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Figure 2.9: (A) Aspect ratio, (B) spheroid fraction and (C) volume of fabricated particles 
as functions of the oil phase fraction for microparticles fabricated from polymer A. PVA 
concentration = 1.0% w/V. Tris concentration = 1.2% w/V. Aqueous phase pH = 8.4. Stir 
rate = 1800 rpm. 
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Figure 2.10: (A) Aspect ratio, (B) spheroid fraction and (C) volume of fabricated 
particles as functions of PLGA polymer end group for microparticles fabricated from 
polymers A, H & I (Table 2.1). PVA concentration = 1.0% w/V. Tris concentration = 
1.2% w/V. Aqueous phase pH = 8.4. Stir rate = 1800 rpm. 
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Figure 2.11: Aspect ratio and spheroid fraction as functions of stir rate for particles 
fabricated from PLGA-PEG (polymer H, Table 2.1). PVA concentration = 1.0% w/V. 
Tris concentration = 1.2% w/V. Aqueous phase pH = 8.4. 
 
 
 
 
 
 
 61 
 
 
 
 
0.0
2.0
4.0
6.0
8.0
40 50 60 70 80 90
A
s
p
e
c
t 
R
a
ti
o
Polymer Molecular Weight (kDa)
 
0
50
100
150
200
40 50 60 70 80 90
V
o
lu
m
e
 (
µ
m
^
3
)
Polymer Molecular Weight (kDa)  
Figure 2.12: (A) Aspect ratio (B) spheroid fraction and (C) volume of fabricated particles 
as functions of the PLGA polymer molecular weight for microparticles fabricated from 
polymers B-D (Table 2.1). PVA concentration = 1.0% w/V. Tris concentration = 1.2% 
w/V. Aqueous phase pH = 8.4. Stir rate = 1800 rpm.  
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Figure 2.13: (A) Aspect ratio, (B) spheroid fraction and (C) volume as functions of the 
PLGA concentration in the oil phase for microparticles fabricated from polymers A. PVA 
concentration = 1.0% w/V. Tris concentration = 1.2% w/V. Aqueous phase pH = 8.4. Stir 
rate = 1800 rpm. 
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Figure 2.14: (A) Aspect ratio, (B) spheroid fraction and (C) volume as functions of mole 
percent lactic acid monomer in the PLGA backbone for microparticles fabricated from 
polymers A, E, F & G (Table 2.1). PVA concentration = 1.0% w/V. Tris concentration = 
1.2% w/V. Aqueous phase pH = 8.4. Stir rate = 1800 rpm. 
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Figure 2.15: (A) Aspect ratio, (B) spheroid fraction and (C) volume of fabricated 
particles as functions of the acetone volume fraction in the oil phase for microparticles 
fabricated from polymer A. PVA concentration = 1.0% w/V. Tris concentration = 1.2% 
w/V. Aqueous phase pH = 8.4. Stir rate = 1800 rpm. 
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Figure 2.16: (A) Aspect ratio and (B) volume polydispersity index of fabricated particles 
as functions of tris concentration in the aqueous phase for microparticles fabricated from 
polymer A. PVA concentration = 2.0% w/V. Aqueous phase pH = 8.4. Stir rate = 1800 
rpm. 
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Table 2.2: Summary of the effects of fabrication parameters on volume and aspect ratio 
polydispersity index of unloaded particles fabricated using the oil-in-water emulsion 
solvent evaporation technique.  
 
Parameter Type Parameter (↑) Aspect Ratio PI Volume PI
System Stir Rate ↓↓↓ ↓↓↓
Oil Phase Fraction ↔ ↔
PLGA conc. ↔ ↓
Oil Phase End Group ↔ ↔
PLGA MW ↔ ↔
PLGA L/G ↓↓↓ ↓
Acetone ↔ ↔
Water Phase Tris ↑↑↑ ↑
pH ↑↑↑ ↔
PVA ↔ ↔  
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Table 2.3: Summary of the effects of fabrication parameters on spheroid fraction, aspect 
ratio and volume of unloaded particles fabricated using the oil-in-water emulsion solvent 
evaporation technique.  
 
Parameter Type Parameter (↑) % Spheroids Aspect Ratio Volume
System Stir Rate ↓ ↓ ↓↓↓
Oil Phase Fraction ↔ ↔ ↓↓↓
PLGA conc. ↑ ↑↑↑ ↔
Oil Phase End Group ↑↑↑ ↑↑↑ ↓
PLGA MW ↓ ↓ ↑
PLGA L/G ↔ ↓ ↑↑↑
Acetone ↔ ↑↑↑ ↔
Water Phase Tris ↓ ↓ ↔
pH ↑↑↑ ↑↑↑ ↔
PVA ↑↓ ↑↓ ↓↓↓  
 
 68 
 
References 
[1] R.G. Larson, The Structure and Rheology of Complex Fluids, Oxford University 
Press, New York, 1999. 
[2] A.O. Eniola, D.A. Hammer, Artificial polymeric cells for targeted drug delivery. J 
Control Release 87(1-3) (2003) 15-22. 
[3] M.J. Heslinga, E.M. Mastria, O. Eniola-Adefeso, Fabrication of biodegradable 
spheroidal microparticles for drug delivery applications. J Control Release 138(3) 
(2009) 235-242. 
[4] G. Gomori, Preparation of Buffers for Use in Enzyme Studies. Methods 
Enzymology 1 (1955) 138-146. 
[5] K. Holmberg, B. Jonsson, B. Kronberg, B. Lindman, Surfactants and Polymers in 
Aqueous Solution, Wiley, West Sussex, 2002. 
[6] W.B. Chu, J.W. Yang, T.J. Liu, C. Tiu, J. Guo, The effects of pH, molecular 
weight and degree of hydrolysis of poly(vinyl alcohol) on slot die coating of PVA 
suspensions of TiO2 and SiO2. Colloids and Surfaces A: Physicochemical and 
Engineering Aspects 302 (2007) 1-10. 
[7] T. Ishijima, Y. Mizumori, K. Kikuchi, A. Suzuki, T. Okaya, Polymerization of 
vinyl acetate in fatty acids and properties of poly(vinyl alcohols) derived from the 
poly (vinyl acetates). Colloid and Polymer Science 283 (2005) 799–804. 
[8] S. Mao, Y. Shi, L. Li, J. Xu, A. Schaper, T. Kissel, Effects of process and 
formulation parameters on characteristics and internal morphology of poly(d,l-
lactide-co-glycolide) microspheres formed by the solvent evaporation method. 
Eur J Pharm Biopharm 68(2) (2008) 214-223. 
[9] L.Y. Wang, G.H. Ma, Z.G. Su, Preparation of uniform sized chitosan 
microspheres by membrane emulsification technique and application as a carrier 
of protein drug. J Control Release 106(1-2) (2005) 62-75. 
[10] M.D. Bhavsar, S.B. Tiwari, M.M. Amiji, Formulation optimization for the 
nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J 
Control Release 110(2) (2006) 422-430. 
[11] F. Cui, M. Yang, Y. Jiang, D. Cun, W. Lin, Y. Fan, Y. Kawashima, Design of 
sustained-release nitrendipine microspheres having solid dispersion structure by 
quasi-emulsion solvent diffusion method. J Control Release 91(3) (2003) 375-
384. 
[12] J.W. McGinity, P.B. O'Donnell, Preparation of microspheres by the solvent 
evaporation technique. Adv Drug Deliv Rev 28(1) (1997) 25-42. 
[13] C. Sturesson, P. Artursson, R. Ghaderi, K. Johansen, A. Mirazimi, I. Uhnoo, L. 
Svensson, A.C. Albertsson, J. Carlfors, Encapsulation of rotavirus into 
poly(lactide-co-glycolide) microspheres. J Control Release 59(3) (1999) 377-389. 
[14] L. Kong, J.K.Beattie, R.J.Hunter, Electroacoustic determination of size and 
charge of sunflower oil-in –water emulsions made by high -pressure 
 69 
 
homogenising. Chemical Engineering and Processing: Process Intensification 
40(5) (2001) 421-429. 
[15] S.M. Butler, M.A. Tracy, R.D. Tilton, Adsorption of serum albumin to thin films 
of poly(lactide-co-glycolide). J Control Release 58(3) (1999) 335-347. 
[16] X.M. Lam, E.T. Duenas, A.L. Daugherty, N. Levin, J.L. Cleland, Sustained 
release of recombinant human insulin-like growth factor-I for treatment of 
diabetes. J Control Release 67(2-3) (2000) 281-292. 
[17] M.A. Tracy, K.L. Ward, L. Firouzabadian, Y. Wang, N. Dong, R. Qian, Y. 
Zhang, Factors affecting the degradation rate of poly(lactide-co-glycolide) 
microspheres in vivo and in vitro. Biomaterials 20(11) (1999) 1057-1062. 
[18] J. Panyam, D. Williams, A. Dash, D. Leslie-Pelecky, V. Labhasetwar, Solid-state 
solubility influences encapsulation and release of hydrophobic drugs from 
PLGA/PLA nanoparticles. J Pharm Sci 93(7) (2004) 1804-1814. 
[19] S.B. Murty, D.H. Na, B.C. Thanoo, P.P. DeLuca, Impurity formation studies with 
peptide-loaded polymeric microspheres Part II. In vitro evaluation. Int J Pharm 
297(1-2) (2005) 62-72. 
[20] S.B. Murty, B.C. Thanoo, Q. Wei, P.P. DeLuca, Impurity formation studies with 
peptide-loaded polymeric microspheres Part I. In vivo evaluation. Int J Pharm 
297(1-2) (2005) 50-61. 
[21] L. Mu, S.S. Feng, A novel controlled release formulation for the anticancer drug 
paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control 
Release 86(1) (2003) 33-48. 
[22] W. Chaisri, W.E. Hennink, S. Okonogi, Preparation and characterization of 
cephalexin loaded PLGA microspheres. Curr Drug Deliv 6(1) (2009) 69-75. 
[23] T.G. Park, H. Yong Lee, Y. Sung Nam, A new preparation method for protein 
loaded poly(D, L-lactic-co-glycolic acid) microspheres and protein release 
mechanism study. J Control Release 55(2-3) (1998) 181-191. 
[24] G. Ruan, S.S. Feng, Preparation and characterization of poly(lactic acid)-
poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for 
controlled release of paclitaxel. Biomaterials 24(27) (2003) 5037-5044. 
[25] R. Bodmeier, J.W. McGinity, Polylactic acid microspheres containing quinidine 
base and quinidine sulphate prepared by the solvent evaporation method. III. 
Morphology of the microspheres during dissolution studies. J Microencapsul 5(4) 
(1988) 325-330. 
 70 
 
CHAPTER III 
Loading therapeutics into prolate spheroids made from biodegradable 
polymers via the oil-in-water emulsion solvent evaporation technique 
Introduction 
The pharmacodynamics, the effect of the drug on the body, and pharmacokinetics, 
the distribution and elimination from the body, of a given drug determines its 
effectiveness of that therapeutic in the treatment of a disease. The route of administration 
plays a vital role in the effectiveness of the drug; uptake and systemic bioavailability of 
the therapeutic depends on the administration. There are many ways to deliver a drug to 
the intended site; typical routes include oral, nasal, dermal, rectal, ocular, intramuscular 
and intravenous delivery. Each route has its own advantages and disadvantages in 
bioavailability, convenience and cost. Oral administration through the swallowing of pills 
offers convenience, but many drugs are poor absorbed in the intestines or may be 
degraded in the low pH of the stomach. Intravenous delivery offers complete 
bioavailability as well as fast action, making it widely used in hospitals, but typically 
requires a medical professional to administer the treatment. The appropriate route of 
administration often depends on the type of therapeutic, disease and patient status.
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Whatever the route of administration, drug delivery via controlled release offers 
several advantages in the treatment of a wide range of diseases. Controlled release forms 
can be made for most methods of drug delivery including oral [1, 2], nasal [3, 4], 
intramuscular and intravenous routes [5-8]. The controlled release of therapeutics utilizes 
the encapsulation of drugs into particles or devices from which the release lasts from 
hours to months. Slow, sustained release permits a lower frequency of dosing, control 
over systemic drug concentrations and protection of fragile drugs.  
Sustained release over time allows for a lower dosing frequency, offering 
increased patient compliance by increasing convenience through decreasing the 
frequency of medication or the number of painful injections. Extended, uniform release 
also provides control over blood concentrations of the drug through designed release 
rates, making it easier to maintain the concentration in the therapeutic window above the 
minimum effective concentration (MEC) yet below the minimum toxic concentration 
(MTC) [9]. Maintaining the drug concentration in the therapeutic window through 
sustained release rather than frequent spikes in and out of this window with traditional 
delivery methods provides more effective treatment as well as reduced side effects. 
Encapsulation of fragile therapeutics in drug delivery carriers can protect the drug load en 
route to its intended destination. Biodegradable polymer microparticles offer promise in 
drug delivery applications due to their biocompatibility, tunable release and flexibility in 
loadable therapeutics. Injectable drug carriers are desirable due to the bioavailability of 
released therapeutics and possibility of targeted, local delivery. 
Many diseases are confined to a small area or organ of the body, making these 
ideal candidates for localized delivery. Additionally, several drugs have a narrow 
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therapeutic window where the MTC is close to the MEC such that these drugs may not be 
effective without targeted delivery. For example, several chemotherapy drugs are highly 
potent, including paclitaxel, which leads to a high incidence of side effects and low 
administered dosages, causing reduced efficacy [10]. Another example are statin drugs 
typically used to lower blood cholesterol levels; studies show statins have anti-
inflammatory effects at dosages higher than systemic MTC, but might be useful if applied 
locally [11, 12].  
Cardiovascular diseases such as CAD are potential candidates for targeted 
delivery due to the unique markers on the vascular wall at the site of diseased tissues due 
to the chronic inflammation present at all disease stages [13]. Targeted drug delivery may 
lower health care costs with smaller, less frequent required dosages with a possible 
reduction in required surgeries in addition to decreasing mortality for CAD and 
improving the quality of life for patients.  
The possible advantages of non-spherical particles for targeted drug delivery 
include more efficient localization to diseased tissues with increased blood circulation 
times as was discussed in detail in Chapter I. The fabrication of biodegradable PLGA 
prolate spheroids by means of the oil-in-water emulsion solvent evaporation method was 
discussed in Chapter II. The loading of therapeutics into polymer particles fabricated 
using the method is vital in the design of optimal drug carriers. Drug load, the mass of 
entrapped drug per total drug carrier mass, and encapsulation efficiency, the ratio of the 
entrapped mass fraction to that of the drug mass fraction present during fabrication, are 
important in the fabrication and effectiveness of drug carriers. Encapsulation efficiency is 
a function of the parameters of the system during fabrication; in general, faster particle 
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solidification during fabrication results in greater encapsulation efficiency since the drug 
has less opportunity to diffuse into the continuous phase [14].  
Several parameters impact the rate of solvent removal and subsequent particle 
solidification rate. Generally, low solubility of polymer in the dispersed phase, high 
solubility of the dispersed phase in the continuous phase, high polymer concentration and 
a low ratio of dispersed phase to continuous phase result in fast solvent removal [15]. 
Increasing the solubility of the polymer in the dispersed oil phase causes slower diffusion 
of the oil phase into the continuous phase, increasing diffusion of the drug and decreasing 
encapsulation efficiency [16-18]. Conversely, increased solubility of the oil phase in the 
water phase causes faster diffusion of the solvent and increases encapsulation efficiency 
[14]. However, addition of a water-soluble co-solvent such as acetone or DMSO may 
increase, decrease or not affect encapsulation depending on the therapeutic characteristics 
[15, 19-22]. The oil phase fraction has been shown to increase encapsulation efficiency 
[23, 24]. Increasing the viscosity of the continuous phase by raising PVA concentration 
slows solvent removal and decreases encapsulation efficiency [25]. Continuous phase pH 
may or may not impact encapsulation efficiency depending on whether or not the 
therapeutic solubility changes with pH [14, 25].  
PLGA prolate spheroids loaded with several therapeutics were manufactured 
using the O/W ESE method to demonstrate the utility of these particles as imaging and 
drug delivery carriers. Therapeutics with potential application in cardiovascular diseases 
were loaded, including paclitaxel as a model hydrophobic drug with potential treatment 
of cancer and to prevent arterial restenosis, lovastatin as an inflammation-reducer in the 
treatment of atherosclerosis, 6-carboxyfluorescein as a fluorescent dye for cardiovascular 
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imaging and cadmium sulfide nanoparticles for fluorescent cardiovascular imaging and to 
demonstrate the loading of nanoparticles into spheroid carriers. The dependence of 
encapsulation efficiency, particle size and particle shape on fabrication parameters, 
including several mentioned above, were examined for paclitaxel-loaded particles. 
Experimental methods 
Microparticle fabrication and characterization 
Drug-loaded microparticles were fabricated from PLGA polymer using the oil-in-
water emulsion solvent evaporation method described in Chapter 2. Drug loading was 
achieved in the O/W ESE through the addition of the desired therapeutic or nanoparticle 
suspension to the oil phase. For paclitaxel and lovastatin loading, 2.5 mg paclitaxel or 
lovastatin were dissolved with 47.5 mg PLGA polymer in 10 ml dichloromethane. For 6-
carboxyfluorescein loading, 1.0 mg 6-CF was dissolved in 1.0 ml ethanol and the 
suspension was added to 9 ml dichloromethane to form the oil phase. For cadmium 
sulfide (CdS) nanoparticle loading, 0.2 mg CdS nanoparticle were suspended in 0.1 ml 
toluene (stock solution) and the mixture combined with 9.9 ml dichloromethane to form 
the oil phase. PLGA polymer A from Table 2.1 was used for all drug loading studies 
unless stated otherwise. The same base conditions as for unloaded particles were utilized 
for drug-loaded particles – the aqueous phase consisted of deionized water at pH 8.4 
(titrated with hydrochloric acid) containing 1.0% w/V PVA and 1.2% w/V tris. The 10 ml 
oil phase was injected over 30 seconds into 100 ml of the aqueous phase while stirred at 
1800 rpm for one hour. Particle size and shape were characterized via light and scanning 
electron microscopy as described in Chapter II. 
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Characterization of drug load and encapsulation efficiency 
Drug load and encapsulation efficiency for all drug-loaded microparticles were 
determined by dissolving dried microparticles in dichloromethane. One mg of freeze-
dried particles loaded with the therapeutic of interest was dissolved in 5 ml 
dichloromethane over 30 minutes and evaluated for concentration. In the case of each 
loaded therapeutic, the measured data was converted into concentration through 
comparison with a calibration curve generated from solutions with known concentrations 
of the drug. The concentration of paclitaxel in the polymer-drug solution was measured 
via UV absorption at 232 nm. Lovastatin-loaded particle drug load was evaluated by UV 
absorption at 237 nm. The concentration of 6-carboxyfluorescein was measured via 
fluorescence with excitation and emission wavelengths of 492/517 nm, respectively. 
Background absorbance or fluorescence of PLGA was subtracted using a similar 
calibration curve. Drug loading was calculated to be the mass of entrapped therapeutic 
divided by the mass of freeze-dried microparticles. Encapsulation efficiency was 
calculated as the ratio of entrapped drug mass to that of the drug mass present in the oil 
phase during fabrication. 
Results and Discussion 
Paclitaxel-loaded PLGA microparticles 
Paclitaxel is a mitotic inhibitor commonly utilized in cancer chemotherapy 
treatments, typically of ovarian, breast and some lung cancers [26-28]. Recent literature 
has shown that paclitaxel can prevent arterial restenosis after percutaneous coronary 
intervention, and thus may be relevant for treatment in cardiovascular disease [29].  The 
loading and release of paclitaxel into microspheres made of biodegradable polymers via 
 76 
 
oil-in-water emulsion solvent evaporation methods has been previously explored in the 
literature and thus was attractive as a model hydrophobic drug [30-33]. Prolate PLGA 
spheroids loaded with paclitaxel at 5.0% (w/w) theoretical load were fabricated using the 
O/W ESE technique as described above. Particles fabricated at the base conditions with 
PLGA polymer A had a spheroid fraction greater than 90% and exhibited drug loading of 
2.7 wt%. These particles were approximately the same volume as unloaded particles and 
showed slightly more deformation with an average aspect ratio of 8.2 (7.0 unloaded). 
These spheroids displayed smooth particle surfaces as shown in Figure 3.1. 
Effect of tris concentration on paclitaxel-loaded spheroids 
The effect of tris base concentration ranging from 0.0% to 1.2% w/V at constant 
PVA concentration (1.0% w/V), aqueous phase pH (8.4), and 5.0% (w/w) theoretical 
paclitaxel load was observed on particle deformation, size and encapsulation efficiency. 
Similar to unloaded particles, only spheres were produced in the absence of tris base 
whereas small concentrations (0.3 – 0.6% w/V) of tris resulted in 90% spheroids with an 
average aspect ratio of 9.6. Further increases in tris base concentration up to 1.2% w/V 
resulted in a decrease in both the average particle aspect ratio and fraction spheroids as 
shown in Figure 3.2. As in the case of unloaded particles, the aqueous phase was held at a 
constant pH via the addition of hydrochloric acid. Increasing concentrations of tris base 
led to a decrease in interfacial tension that was counteracted by the corresponding 
increase in electrolytes required to maintain pH 8.4 in the aqueous phase. Increased 
electrolyte concentration decreased the PVA concentration at the interface and also 
decreased the solubility of the oil phase in the water phase as discussed in Chapter 2 [34]. 
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 Varying tris base concentration over this range showed no effect on the 
encapsulation efficiency of paclitaxel (Figure 3.2), unsurprising since paclitaxel is poorly 
soluble in the water phase due to its hydrophobic nature. Increasing electrolyte 
concentrations required to maintain constant pH at increasing tris concentrations does not 
significantly alter the solubility of paclitaxel and thus has little impact on the loading 
efficiency of the encapsulated drug. 
Effect of aqueous phase pH on paclitaxel-loaded spheroids 
Paclitaxel-loaded particles were fabricated from buffers varying in aqueous phase 
pH between 7 and 10 for constant PVA and tris base concentrations (1.0% and 1.2% w/V, 
respectively) at 5.0% w/w theoretical load. As seen with unloaded particles, paclitaxel-
loaded particles formed spheroids only at basic aqueous phase pH. Figure 3.3 shows that 
as the water phase pH increased from 7 to 9, the fraction of particles that were spheroids 
increased from 1% to 91% with an average aspect ratio of 7.4. Further increase to water 
phase pH 10 resulted in decreased particle elongation with a reduction in spheroid 
fraction to 62% and spheroid aspect ratios to 5.1. Again, lower pH at a fixed 
concentration of tris was achieved via the addition of hydrochloric acid which increased 
the electrolyte concentration, resulting in decreased droplet deformation and resultant 
particle elongation through decreased surface concentration of PVA and decreased oil 
phase solubility [34]. Aqueous buffers containing 1.0% w/V PVA and 1.2% w/V tris with 
no acid added exhibited pH 9.3. Reduction in pH was achieved through acid addition 
while an increase to pH 10.0 was attained via sodium chloride addition; electrolyte 
concentration increased in both cases. 
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Encapsulation efficiency of paclitaxel was unchanged with the variation of 
aqueous phase pH (Figure 3.3) as observed with the variation of tris base concentration. 
Since paclitaxel is highly hydrophobic, it is not sensitive to the change in electrolyte 
concentration and its solubility is not aqueous phase pH dependent.  
Effect of polyvinyl alcohol concentration on paclitaxel-loaded spheroids 
Particles loaded with paclitaxel were fabricated from aqueous phases containing 
PVA concentrations varying from 0.5% to 2.0% w/V at constant tris base (1.2% w/V), 
aqueous phase pH (8.4), and 5.0% w/w theoretical drug load. Particle shape and volume 
showed the same trend with PVA concentration as with unloaded particles; as the PVA 
concentration increased to 1.5% (w/V), the particle aspect ratio increased from 3.9 to 4.8 
and then decreased to 4.0 with further PVA increase to 2.0% (w/V) (Figure 3.4). There 
was no significant difference in the spheroid fraction over this PVA range. The average 
particle volume decreased from 140 um
3
 to 60 um
3
 and drug encapsulation efficiency 
decreased from 54% to 26% as PVA concentration increased from 0.5% to 2.0% w/V 
(Figure 3.4).  
PVA is a surface active polymer that not only acts as the emulsifier, but also 
increases aqueous phase viscosity. This directly increases the capillary number and 
decreases the viscosity ratio, leading to increased droplet deformation. However, as in the 
case of unloaded particles, increasing the capillary number also leads to increased droplet 
breakup and smaller particle volumes. High concentrations of PVA in the aqueous phase 
led to the crowding of the interface between the phases. The combination of a high 
aqueous phase viscosity and crowded interface slow the solvent diffusion rate into the 
water phase. This slowed solidification and increased surfactant concentration permit 
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more paclitaxel leakage and a corresponding decrease in the encapsulation efficiency as 
has been previously observed [25]. 
Effect of acetone co-solvent on paclitaxel-loaded spheroids 
The organic solvent used in the dispersed oil phase impacts the particle size and 
deformation as well as the loading efficiency of therapeutics in oil-in-water emulsion 
systems. Particles loaded with paclitaxel were fabricated with oil phases composed of 0% 
or 50% volume fraction acetone as a co-solvent with dichloromethane while holding the 
total volume of the oil phase constant at 10 ml. When the acetone volume fraction was 
increased from 0% to 50%, the particle aspect ratio increased slightly from 7.5 to 9.0 and 
the fraction spheroids remained unchanged (85% to 92%) (Figure 3.5). However, the 
particle volume increased significantly, jumping from 110 µm
3 
with no acetone co-
solvent to 200 µm
3
 at 50% acetone by volume. This differs significantly from the 
unloaded particles where volume was unchanged and aspect ratio almost doubled with 
acetone used as co-solvent. Paclitaxel is sparingly soluble in acetone and highly soluble 
in dichloromethane such that acetone diffuses into the water phase quickly upon injection 
and little paclitaxel is carried with it. The remaining oil phase consists almost entirely of 
dichloromethane and behaves as if the oil phase fraction has been reduced. This leads to 
an increase in particle volume as observed with low oil phase fractions with unloaded 
particles. The encapsulation efficiency was unaffected by the use of acetone as a co-
solvent as has been observed in literature [19-21]. Paclitaxel is poorly soluble in water 
and acetone and therefore mostly remains within the dichloromethane in the oil phase.  
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Effect of oil volume fraction on paclitaxel-loaded spheroids 
Prolate spheroids loaded with paclitaxel were fabricated at two different oil-to-
aqueous phase volume ratios while keeping all other process parameters constant. As the 
volume fraction of oil phase doubled from 0.09 to 0.18 at constant total volume (water 
plus oil phases) of 110 ml, the particle volume decreased slightly from 110 to 100 μm3, 
following the same trend observed with unloaded particles (Figure 3.6). Increased 
dispersed phase fraction changes the average particle volume due to an increase in 
viscosity of the solution [35]. Particle aspect ratio decreased with increasing oil phase 
volume fraction as shown in Figure 3.6. Greater solution viscosity due to higher 
dispersed phase volume fraction led to greater shear forces and an increased capillary 
number; the decrease in particle volume due to breakup led to a net decrease in droplet 
deformation as the smaller droplets decrease the capillary number. Decreasing particle 
size with increasing oil phase volume fraction has been previously observed for oil-in-
water emulsions [36]. Drug load and encapsulation efficiency increased with larger oil 
phase volume fraction (Figure 3.6), most likely due to the decreased particle size 
observed at the higher ratio as previously reported in the literature [19-21]. 
Lovastatin-loaded PLGA Spheroids 
Oral dosing of statins is currently utilized to reduce systemic low-density 
lipoprotein (LDL) cholesterol concentrations in the preventative treatments of coronary 
artery disease in an effort to decrease the amount of plaque buildup in the patient’s 
arteries during atherosclerosis, the precursor to coronary artery disease. Statins have also 
been shown to have potent anti-inflammatory effects on human umbilical vein 
endothelial cells (HUVECs) in cell culture and in inflammation models in animals [11, 
 81 
 
12]. Such anti-inflammatory treatments may offer additional benefits in the treatment of 
chronic inflammatory diseases, such as atherosclerosis, yet these effects are only realized 
at concentrations too high for systemic delivery due to the deleterious side effects. 
Localized delivery of such therapeutics through inflammation-targeting may offer an 
opportunity to utilize the anti-inflammatory effects of statin drugs by locally producing 
elevated concentrations while keeping systemic blood concentrations low, thereby 
limiting side effects [12].   
PLGA particles loaded with 5.0% w/w lovastatin (theoretical load) were 
fabricated with aqueous buffers containing 1.0% w/V PVA and 0.6% w/V tris base at pH 
8.4. The resultant spheroids (Figure 3.7) had an average aspect ratio of 7.4 with an 
average volume of 163 µm
3
. These particles exhibited an encapsulation efficiency of 
42%, corresponding to a lovastatin load of 2.1% w/w. Targeted drug delivery from 
lovastatin-loaded spheroids offer potential treatments for chronic inflammatory diseases 
such as atherosclerosis. 
PLGA spheroids for imaging – loading 6-carboxyfluorescein (6-CF) 
Vascular-targeted imaging particles may prove useful in the identification of 
cardiovascular diseases and their subsequent treatment. For example, such particles may 
permit the early identification of atherosclerosis and help in the discrimination between 
stable and vulnerable plaques, yielding information critical in the treatment of such 
diseases [37]. Sensitive imaging capabilities may guide surgeons as they repair vascular 
injuries and improve understanding of the underlying causes of coronary artery as well as 
other cardiovascular diseases. Spheroids loaded with contrast agents for imaging offer 
potential for improving treatments options through efficient disease imaging. Fluorescent 
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dyes are easily measured and quantified, allowing for in vitro and in vivo evaluation of 
binding to inflammation models. 6-carboxyfluorescein (6-CF) is a fluorescent derivative 
of fluorescein often used to quantify ion movement across cell membranes [38].  6-CF is 
attractive as a fluorescent dye for both imaging experiments and for evaluating the 
release of loaded therapeutics from biodegradable polymer particles [39].  
The effect of tris base concentration on 6-CF-loaded spheroids 
The effect of tris concentration in the aqueous phase on 6-CF-loaded particles was 
examined for tris concentrations between 0.0% and 1.2% w/V at 1.0% w/V PVA 
concentration, aqueous phase pH 8.4, and 1.0% w/w theoretical 6-CF load. 6-CF is 
anionic at neutral (and basic) pH through the donation of the hydrogen from its alcohol 
group with a pK of 6.3. Accordingly, its solubility in dichloromethane is sparing at 
neutral and basic pH while its solubility drastically increases below pH 6.3 (pK for the 
alcohol group) and pH 4.5 where the terminal carboxyl forms a ring structure as shown in 
Figure 3.8 [38]. The partition coefficient therefore drastically decreases at pH greater 
than 6.3. In order to increase solubility in the oil phase, the drug was initially dissolved in 
ethanol prior to addition to dichloromethane at a ratio of 10:90 ethanol:dichloromethane, 
utilizing ethanol as a co-solvent. 
Fabricated particles followed a similar trend as unloaded and paclitaxel-loaded 
particles; a minimum tris concentration of 0.3% w/V was required for particle elongation 
due to the decrease in interfacial tension between the oil and aqueous phases with the 
addition of tris. Further increases in tris concentration up to 1.2% w/V led to a decrease in 
the fraction spheroids and spheroid aspect ratio as shown in Figures 3.9. As stated before 
for unloaded and paclitaxel-loaded particles, this is a result of increasing acid 
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concentration with increasing tris concentration required to hold the water phase pH at 
8.4. The result is decreased surface activity and concentration of PVA and decreased oil 
phase solubility in the water phase. 
As seen with the loading of paclitaxel, changing tris concentration did not 
significantly alter the loading efficiency of 6-CF for particles fabricated with any amount 
of tris in the aqueous buffer. However, unlike with paclitaxel, particles fabricated in the 
absence of tris showed very low loading efficiencies (Figure 3.9). It took twelve times the 
original 6-CF load (12% w/w theoretical load) to increase the actual drug load of loaded 
particles made in the absence of tris to a level comparable to those made with 1% w/w 6-
CF in any tris concentration (Table 3.1). Particles made in the absence of tris were 
spheres while those fabricated in the presence of a small tris concentration were nearly all 
rods. In order to verify that particle geometry was not solely responsible for the 
difference in drug loading efficiency, tris concentration was increased to 6.0% w/V in the 
aqueous buffer where the high electrolyte concentration increased the interfacial tension 
enough to show no particle elongation (spheres). Table 3.1 shows that insensitivity of 
encapsulation efficiency to tris concentration – spheres produced at 6.0% w/V tris and pH 
8.4 displayed similar drug loading efficiency as rods made at low tris concentrations and 
the same pH. 
Tris is a surface active base that interacts with the polymer end groups, lowering 
the interfacial tension between the oil and water phases in this emulsion system. Due to 
its relatively high solubility in water when compared to that of dichloromethane, the 
ethanol in the oil phase diffuses rapidly into the water phase upon emulsification. Since 
the 6-CF is also water soluble and has a low partition coefficient at neutral pH, it too will 
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diffuse rapidly in comparison to DCM into the water phase resulting in low encapsulation 
efficiencies in the absence of tris base as seen with other highly water soluble drugs 
encapsulated using O/W ESE methods [15]. When tris is present in the water phase, the 
interfacial tension is lowered and increases the diffusion of DCM into the water phase as 
well as water into the oil phase. Tris enters along with the small volume of water and is 
protonated upon contact with 6-CF within the oil phase, making the drug anionic in the 
presence of the base and drastically changing its solubility in the remaining DCM within 
the droplet. Thus the 6-CF likely precipitates within the oil phase due to the change in 
solubility and cannot pass the interface, increasing the encapsulation efficiency. Even a 
low concentration of tris is enough to cause ionization and precipitation of 6-CF, 
rendering loading efficiency insensitive to tris concentration. This hypothesis was tested 
using confocal microscopy to observe the 6-CF distribution within the particles. Figure 
3.10 shows the fluorescent dye loading of spheres and spheroids; the spheres were 
manufactured in the absence of tris while loaded spheroids were made with tris in the 
aqueous phase. Spheroids show non-uniform loading due to the precipitation of 6-CF in 
the oil phase while spheres show uniform loading in the absence of tris. 
Nanosphere-loaded spheroids 
Successful targeted drug delivery or imaging systems must reach their target in 
functional form. This requires navigating blood flow by avoiding the natural clearance 
processes, finding the target on the vessel wall from flow and binding specifically at the 
objective. Nanospheres are much less likely to be phagocytosed than larger, micron-sized 
particles, likely resulting in longer circulation times [40]. Increased blood circulation 
time is likely due to a decreased opsonization rate with decreasing particle size [41]. 
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Opsonization refers to the absorption of serum proteins onto foreign particles as the 
primary step in clearance from the body [41, 42]. However, nanospheres have been 
shown to be inefficient in vascular targeting as the localization and binding to inflamed 
human umbilical vein endothelial cells (HUVECs) from blood flow was significantly 
lower for nanospheres from 100 – 500 nm compared to that of micron-sized spheres [43, 
44]. The final destination of the drug delivery or imaging system may not be the vascular 
endothelium, but rather the underlying tissue. It is possible that loaded drug/imaging 
agents may not be able to permeate the endothelial cell layer lining the vessel wall; in this 
case nanoparticles may be designed for internalization or transcytosis of the endothelium 
[45, 46]. However, the low binding efficiency of nanoparticles remains problematic. 
One possible approach to solving this problem may be the embedding of 
nanovectors within micron-sized spheroids that have high efficiency in traveling to the 
vessel wall and improved circulation times due to their size and geometry. The 
microspheroids would bind to the endothelium and release the loaded nanocarriers at the 
vessel wall where they could transmigrate through the endothelium to diseased tissues. 
This requires microcarrier design appropriate to release their load over the desired time 
frame, perhaps utilizing fast degrading polymers for fast release. Imaging systems may 
include either loaded nanovectors for release or remain within the microspheroids at the 
endothelial surface; for example, nano-sized gadolinium contrast agents loaded into 
porous silicon microspheres showed enhanced contrast due to their geometrical 
confinement [47]. Iron oxide nanoparticles might be of particular interest for imaging due 
to their application in magnetic resonance imaging (MRI) applications for use in humans. 
MRI is more attractive than fluorescence due to its visibility through deep tissue. 
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One unique approach for treating atherosclerosis may be the targeting of the 
neovascularization of the vasa vasorum, a network of small arteries penetrating the vessel 
wall providing blood flow to the tissue, which is correlated with atherosclerotic plaque 
growth and rupture [48]. Inflammation and angiogenesis associated with atherosclerosis 
may provide an avenue for targeting; however, only circumstantial evidence exists for 
nanoparticles localizing to the vasa vasorum [49]. Additionally, the orientation of the 
vasa vasorum is important for targeting as some of these vessels originate from the lumen 
of arteries [50]. 
Spheroids loaded with cadmium sulfide nanospheres 
Cadmium sulfide (CdS) nanospheres are fluorescent with excitation wavelengths 
between 430 and 450 nm and emission wavelengths 445 – 470 nm. PLGA particles were 
loaded with 5 nm CdS nanospheres in order to demonstrate the concept of loading 
nanoparticles into micron-sized spheroids and their potential use for cardiovascular 
imaging or drug delivery (Figure 3.11). CdS-loaded particles were fabricated from 
aqueous buffers containing 3.0% w/V PVA and 0.6% w/V tris base at pH 9.0. Stock CdS 
particles were dissolved in toluene at 2 mg/ml concentration and oil phases containing 
0.2% w/w CdS consisted of 0.1 ml toluene in 9.9 ml dichloromethane. Particles 
fabricated at these concentrations consisted of 93% spheroids with an average aspect ratio 
of 11.9 ± 1.1 and an average particle volume of 292 ± 12 µm
3
.  
Summary 
Spheroids loaded with a range of therapeutics and imaging agents were fabricated 
utilizing the oil-in-water emulsion solvent evaporation technique. Encapsulated drugs and 
imaging agents included hydrophobic (paclitaxel and lovastatin) and water-soluble (6-
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carboxyfluorescein) drugs as well as nanoparticles (cadmium sulfide). The loaded 
therapeutics show the ability of these particles to act as drug delivery carriers while the 
loaded imaging agents allow these particles to be useful as contrast agents. Regardless of 
the loaded molecule or nanoparticles, all loaded particles displayed similar dependences 
on system parameters for particle size and shape as with unloaded particles. 
Encapsulation efficiency was drug-dependent, however, as each loaded agent responded 
differently to loading conditions. Paclitaxel showed loading consistent with that reported 
in literature by hydrophobic chemical drugs while 6-carboxyfluoroscein loading 
efficiency depended largely on the presence of tris base in the aqueous phase, which 
changed the dye solubility in the oil phase and caused precipitation within the oil phase.
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Figure 3.1: Paclitaxel-loaded PLGA prolate spheroids fabricated using the oil-in-water 
emulsion solvent evaporation technique. 
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Figure 3.2: (A) Aspect ratio, (B) spheroid fraction, (C) volume and (D) paclitaxel 
encapsulation efficiency as functions of the aqueous phase tris concentration for 
microparticles fabricated from polymer C (Table 2.1). PVA concentration = 1.0% w/V. 
Stir rate = 1800 rpm. Aqueous phase pH = 8.4. Theoretical paclitaxel load = 5.0% w/w. 
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Figure 3.3: (A) Aspect ratio, (B) spheroid fraction, (C) volume and (D) paclitaxel 
encapsulation efficiency as functions of the aqueous phase pH for microparticles 
fabricated from polymer C. PVA concentration = 1.0% w/V. Tris concentration = 1.2% 
w/V. Stir rate = 1800 rpm. Theoretical paclitaxel load = 5.0% w/w. 
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Figure 3.4: (A) Aspect ratio, (B) spheroid fraction, (C) volume and (D) paclitaxel 
encapsulation efficiency as functions of the aqueous phase PVA concentration for 
microparticles fabricated from polymer C. Tris concentration = 1.2% w/V. Stir rate = 
1800 rpm. Aqueous phase pH = 8.4. Theoretical paclitaxel load = 5.0% w/w. 
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Figure 3.5: (A) Aspect ratio, (B) spheroid fraction, (C) volume and (D) paclitaxel 
encapsulation efficiency as functions of the acetone volume fraction in the oil phase for 
microparticles fabricated from polymer C. PVA concentration = 1.0% w/V. Tris 
concentration = 1.2% w/V. Stir rate = 1800 rpm. Aqueous phase pH = 8.4. Theoretical 
paclitaxel load = 5.0% w/w. 
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Figure 3.6: (A) Aspect ratio, (B) spheroid fraction, (C) volume and (D) paclitaxel 
encapsulation efficiency as functions of the oil phase fraction for microparticles 
fabricated from polymer C. PVA concentration = 1.0% w/V. Tris concentration = 1.2% 
w/V. Stir rate = 1800 rpm. Aqueous phase pH = 8.4. Theoretical paclitaxel load = 5.0% 
w/w. 
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Figure 3.7: Scanning electron microscopy image of lovastatin-loaded prolate spheroids 
fabricated from PLGA polymer C using the oil-in-water emulsion solvent evaporation 
technique. 
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Figure 3.8: Molecular structure of 6-carboxyfluorescein (6-CF) for different environment 
pH values. The pK values of 6CF are 4.5 and 6.3. 
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Figure 3.9: (A) Aspect ratio, (B) spheroid fraction, (C) volume and (D) 6-
carboxyfluorescin encapsulation efficiency as functions of the aqueous phase tris 
concentration for microparticles fabricated from polymer C. PVA concentration = 1.0% 
w/V. Stir rate = 1800 rpm. Aqueous phase pH =8.4. Theoretical 6CF load = 1.0% w/w. 
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Figure 3.10: Confocal microscope images of 6-carboxyfluorescein-loaded spheres and 
rods. Loaded spheroids were fabricated with tris in the aqueous phase while loaded 
spheres contained no tris in the aqueous phase. Spheres show an even distribution of 6CF 
while spheroids show non-uniform 6CF loading due to the precipitation of the drug 
within the oil phase due to the presence of tris. 
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Table 3.1: 6-carboxyfluorescein loading efficiencies of prolate spheroids and spheres 
made from PLGA polymer C in the presence or absence of tris base. 
Shape
Tris                
(w/V)
Theoretical 
Load (w/w)
Actual Load 
(w/w)
Loading 
Efficiency
Rods 0.6% 1% 0.39% 39%
Spheres 0.0% 1% 0.03% 3.0%
Spheres 0.0% 5% 0.21% 4.2%
Spheres 0.0% 12% 0.35% 2.9%
Spheres 6.0% 1% 0.43% 43%  
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Figure 3.11: Prolate spheroids loaded with 5 nm cadmium sulfide (CdS) fluorescent 
nanoparticles made from PLGA polymer C using the oil-in-water emulsion solvent 
evaporation system. 
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CHAPTER IV 
Loading protein therapeutics via the water-in-oil-in-water (W/O/W) 
emulsion solvent evaporation technique 
Introduction 
Loading of bovine serum albumin into PLGA spheroids 
Recent advances in the number of protein and peptide drugs available for 
therapeutic treatment of several diseases, including many cardiovascular diseases, has 
created the need for methods to effectively administer these protein drugs [1-4]. 
Controlled, targeted release of this class of therapeutics may be required in many cases 
due to the poor bioavailability of these therapeutics through non-parenteral routes. For 
example, oral administration is impractical for proteins and peptides due to the 
degradation and poor uptake in the gastrointestinal tract. Additionally, proteins drugs 
typically have short half-lives in the body due to natural clearance processes, requiring 
repeated dosing. 
The encapsulation of protein drugs within injectable, targeted microparticles made 
from biodegradable polymers for controlled drug release at the site of disease offers 
potential for increasing the efficacy of these therapeutics and maintaining necessary
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concentrations at affected tissues. Oil-in-water emulsions are not useful for making 
protein-loaded particles due to poor solubility and possible damage to the therapeutic in 
the oil phase. Therefore, encapsulation of pharmaceutical proteins into biodegradable 
drug carriers has typically used water-in-oil-in-water (W/O/W) double emulsion 
techniques in order to stabilize the protein and improve loading efficiency over single 
emulsion techniques [5, 6]. In the W/O/W technique, the protein is loaded into the inner 
aqueous phase and a primary emulsion is made by mixing with the oil phase containing 
the biodegradable polymer. A secondary emulsion is made by injection of the W/O 
emulsion into the outer aqueous phase. The oil phase acts as a barrier to separate the two 
aqueous phases, permitting high encapsulation efficiency while the protein remains stable 
in the inner water phase. 
 Bovine serum albumin (BSA) is attractive as due to its common use in protein 
assays as well as its stability, low reactivity and low cost. As such, BSA is a prototypical 
protein drug that has previously been loaded into PLGA particles [7-10]. Serum albumin 
is the most abundant plasma protein in mammals and is utilized in the body to maintain 
the osmotic pressure of plasma in order to stabilize the extracellular fluid volume. It is a 
soluble serum protein with molecular weight around 66 kDa and comprises about half of 
the blood serum protein by mass. Bovine serum albumin was loaded as a model protein 
drug and as a demonstration of the production of rods from the W/O/W solvent 
evaporation method in order to expand the range of usable therapeutics from small, 
hydrophobic chemical drugs to protein drugs. 
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Experimental methods 
Microparticle fabrication and characterization 
Bovine serum albumin-loaded microparticles were fabricated from PLGA 
polymer using the water-in-oil-in-water emulsion solvent evaporation method. 
Specifically, the inner water phase consisted of 2.5 mg BSA and 0.5% w/V PVA in 0.5 
ml deionized water. The oil phase contained 49.5 mg PLGA polymer (polymer C, Table 
2.1) dissolved in 10 ml dichloromethane. The outer water phase contained 3.0% w/V 
PVA and 0.6% w/V tris dissolved in 100 ml deionized water held at pH 9.0 through the 
addition of hydrochloric acid. A primary emulsion was formed via mixing of the inner 
water phase with the oil phase followed by sonication of the emulsion at 10W for 60 
seconds with a 3 mm sonication probe. The primary emulsion was injected into the outer 
water phase over 30 seconds and stirred at 1800 rpm for 3 hours at room temperature. 
Resultant particles were collected and washed three times via centrifugation at 750 rpm 
in deionized water as described in Chapter II. Particle size and shape were characterized 
via light and scanning electron microscopy as described in Chapter II. BSA-loaded 
PLGA particles displayed rough surface characteristics as shown in Figure 4.1. 
Characterization of drug load and encapsulation efficiency 
Drug load and encapsulation efficiency for BSA-loaded microparticles were 
determined by dissolving dried microparticles in dichloromethane 30 minutes. One mg of 
freeze-dried particles loaded with the BSA was dissolved in 5 ml dichloromethane over 
30 minutes. The BSA was then extracted into deionized water through liquid-liquid 
extraction with deionized water over one hour. The BSA-rich aqueous phase was 
removed and its BSA concentration evaluated using UV absorbance at 280 nm and 
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comparing readings to calibration curves generated using free BSA and PLGA polymer. 
Drug loading was calculated to be the mass of entrapped paclitaxel divided by the mass 
of freeze-dried microparticles. Encapsulation efficiency was calculated as the ratio of 
entrapped drug mass fraction to that of the drug mass fraction present in the oil phase 
during fabrication. 
Results and Discussion 
The effect of polyvinyl alcohol on bovine serum albumin-loaded PLGA particles 
PLGA particles were fabricated with 2.5% w/w theoretical load BSA using the 
W/O/W ESE technique at PVA concentrations varying from 1.0% to 4.0% w/V in the 
aqueous buffer with 0.6% w/V tris base concentration at constant aqueous phase pH 9.0. 
As the PVA concentration increased from 1.0% to 3.0% w/V, the resultant particles 
increased in fraction spheroids from 42% to 86% and average particle aspect ratio from 
2.9 to 5.2 (Figure 4.2). Further increase in PVA up to 4.0% w/V decreased the fraction 
spheroids to 70% and particle aspect ratio to 4.0. Additionally, the average particle 
volume decreased with increasing PVA concentration, decreasing from 1000 to 160 µm
3
 
as PVA concentration increased from 1.0 to 4.0% w/V. 
Particle size and shape follow the same trend as observed in unloaded and 
paclitaxel-loaded particles (Chapters II and III). PVA acts in a dual role in this emulsion 
system; it acts as the surfactant leading to the droplet formation through emulsification 
and also acts to increase aqueous phase viscosity. Increasing the continuous phase 
viscosity increases the capillary number and decreases the viscosity ratio, leading to not 
only increased droplet deformation but also droplet breakup [11]. There is a tradeoff 
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between deformation and breakup that is dominated by decreasing droplet size through 
breakup at high PVA concentrations. 
Unlike the trend observed for the hydrophobic drug paclitaxel in the O/W ESE 
technique, the encapsulation efficiency of BSA increased with increasing PVA 
concentration in the aqueous buffer (Figure 4.2). As was the case in the loading of 
paclitaxel, high PVA concentrations in the aqueous phase led to the crowding of the 
interface between the phases. While this slowed the solvent removal that led to decreased 
loading efficiency with paclitaxel, in the W/O/W system the crowded interface serves to 
prevent the large BSA molecules from crossing the interface due to their high molecular 
weight. Additionally, increased surfactant concentration on the surface decreases the 
chance that inner water phase droplets merge with the outer water phase upon contact by 
stabilizing the interface and the inner water phase droplets. Therefore, high encapsulation 
efficiencies of BSA, up to 95%, were observed at high PVA concentrations. 
The effect of aqueous phase pH on bovine serum albumin-loaded PLGA particles 
The effect of external aqueous phase pH ranging from 5.0 to 10.0 was observed 
for BSA-loaded particles in the W/O/W ESE method. The pH of the aqueous phase was 
modified via the addition of either hydrochloric acid (pH 5.0, 7.0, 8.4, 9.0) or sodium 
hydroxide (pH 10.0) since the pH of the water phase started at 9.1 prior to titration.  
Similar to unloaded particles, basic external water phase pH was required for the 
formation of spheroids as all spheres were produced at pH 5.0 and few rods at pH 7.0. As 
the aqueous phase pH increased from 5.0 to 8.4, particle elongation (aspect ratio) 
increased from 1.0 to 6.4 and spheroid fraction increased from 0% to 88% (Figure 4.3). 
Further increase up to pH 10.0 produced no significant difference in spheroid fraction, 
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but decreased aspect ratio to 4.9. The pK of tris is around 8.1 and aqueous phase pH 
below this results in the protonation of the amine group, reducing the interaction between 
tris and polymer end groups at the edge of the oil phase. The pH also influences the 
effectiveness of the surfactant PVA, causing higher interfacial tension at low pH [12, 13]. 
The higher electrolyte concentration required to move the pH up or down from 9.1 
decreases the solubility of the oil phase in the aqueous phase, raising interfacial tension 
(decreasing the capillary number) between the phases and allowing no particle stretching 
at high electrolyte concentrations (low pH) [14]. 
Unlike observed for the hydrophobic drug paclitaxel in the O/W ESE technique, 
the encapsulation efficiency of BSA increased with increasing aqueous phase pH up to 
pH 9.0 and decreased upon further increase to pH 10.0 (Figure 4.3). This loading 
efficiency is directly proportional to the amount of hydrochloric acid or sodium 
hydroxide added – very little hydrochloric acid (less than 200 μl) was required to bring 
the pH to 9.0 while significantly more (more than 0.5 ml) HCl or NaOH was needed for 
pH 8.4 or 10.0, respectively. Further HCl was needed to bring the buffer pH below the 
pK of tris base (8.1) to pH 7.0 or 5.0. Increasing electrolyte concentrations decrease the 
effectiveness of PVA as a surfactant, decreasing crowding (PVA concentration) on the 
surface of the interface. Interruption of the interface allows greater diffusion of the high 
molecular weight BSA to cross as well as a greater chance for the inner and outer water 
phases to merge, decreasing the amount of encapsulated BSA. Additionally, BSA 
changes conformation based on pH of its surroundings. It has its normal (N) 
conformation from pH 4 – 8 with elongated forms at acidic (E and F conformations) and 
basic (B conformation) pH as seen in Figure 4.4 [15, 16]. While BSA remains water 
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soluble at all conformations, increasingly basic pH causes BSA to be increasingly 
negatively charged, stabilizing the inner water phase by increasing the interfacial tension 
between it and the oil phase. Stabilized inner water droplets are less likely to merge with 
the outer water phase, increasing BSA encapsulation. 
Summary 
Bovine serum albumin was loaded as a model pharmaceutical protein via a water-
in-oil-in-water emulsion solvent evaporation technique. Particles loaded with BSA 
showed similar trends for volume and aspect ratio as unloaded and loaded particles made 
by the O/W ESE method. However, the encapsulation efficiency for BSA showed a 
unique dependence on PVA and aqueous phase pH unobserved with small chemical 
drugs loaded by single emulsion methods. Parameters that stabilized the inner water 
phase, including basic aqueous pH and high surfactant concentration, increased the 
encapsulation efficiency of BSA. 
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Figure 4.1: Bovine serum albumin-loaded PLGA particles fabricated using the water-in-
oil-in-water (W/O/W) emulsion solvent evaporation technique. 
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Figure 4.2: (A) Aspect ratio, (B) spheroid fraction, (C) volume and (D) encapsulation 
efficiency of bovine serum albumin as functions of the PVA concentration for 
microparticles fabricated from polymer C. Tris concentration = 0.6% w/V. Stir rate = 
1800 rpm. Aqueous phase pH = 9.0. Theoretical BSA load = 2.5% w/w. 
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Figure 4.3: (A) Aspect ratio, (B) spheroid fraction, (C) volume and (D) encapsulation 
efficiency of bovine serum albumin as functions of the aqueous phase pH for 
microparticles fabricated from polymer C. PVA concentration = 3.0% w/V. Tris 
concentration = 0.6% w/V. Stir rate = 1800 rpm. Theoretical BSA load = 2.5% w/w.  
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Figure 4.4: The dependence of isometric forms of bovine serum albumin on 
environmental pH [15]. 
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CHAPTER V 
Therapeutic release from loaded PLGA spheroids 
Introduction 
The release profile of loaded therapeutics is critical to the appropriate design of a 
drug delivery system. Not only does the rate of release determine the local (if targeted) or 
systemic concentration in vivo, but it also affects several considerations to the broader 
treatment plan including dosage amount and frequency [1]. The release of a particular 
therapeutic is dependent on several variables of the system including the characteristics 
of the drug itself. One variable of interest is particle geometry; the release of loaded 
therapeutics from non-spherical particles fabricated via the oil-in-water emulsion solvent 
evaporation technique described within and how this release differs from loaded spheres 
is important in the design of an optimal drug delivery system [2].  
Release profiles from loaded spheres and spheroids needed to be examined since 
the rate and duration of release of loaded therapeutics is vital in determining possible 
dosage plans. The increased surface area-to-volume ratio of non-spherical particles, 
including spheroids, should result in a shorter diffusion path for loaded drug into the 
external release media and that media into the particle. Increasing the 
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water uptake of the particle should result in faster release due to particle swelling and 
degradation causing larger pore diameters. Diffusion based release can be described by 
Fick’s Second Law for particles differing in size and shape. The model compares spheres 
and spheroids of varying aspect ratios of the same particle volume and drug load, 
assuming uniform load throughout the particle polymer matrix. Fick’s Second Law 
without generation yields: 
CD
dt
dC 2   Eqn. (5.1) 
where C is concentration, t is time and D is the diffusion coefficient of the 
therapeutic in the particle. The solution of Equation 5.1 is a series solution for 
concentration at a given position at a given time. Each geometry has its own solution that 
is well characterized for straightforward diffusion [3]: 
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Drug release over time can be calculated by subtracting the remaining entrapped 
therapeutic from the starting mass of drug. The remaining loaded drug is determined by 
integrating the concentration over the total particle volume, which is assumed to remain 
constant with time. The fractional loss of loaded therapeutic is the mass lost divided by 
the original mass: 
 0
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
  Eqn. (5.4) 
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The fractional loss gives the drug release over time. This diffusion model can be 
fit to experimental data in order to determine the diffusion constant for the drug within 
the PLGA particle. Diffusion coefficients are constant for a given drug molecule in a 
given material system. Such a diffusion model can be utilized to predict how shape 
affects drug release from particles of the same material. Figure 5.1 shows the prediction 
of the model for diffusion-controlled release from prolate spheroids and spheres – the 
shorter diffusion path of the prolate spheroids is predicted to result in faster release rates 
than spheres of the same volume. Additionally, higher aspect ratios show faster drug 
release due to the shorter diffusion path and larger particle surface area for a given 
volume.   
Experimental methods 
Microparticles loaded with paclitaxel or 6-carboxyfluorescein were fabricated 
utilizing O/W ESE methods as described in previous chapters. The drug loading and 
encapsulation efficiency were characterized for the loaded particles. In vitro drug release 
studies were conducted in 10 mM phosphate-buffered saline (PBS) at pH 7.4 and 37°C.  
Five mg of drug-loaded microparticles were suspended in 10.0 ml of PBS in screw-
capped polypropylene tubes and placed on a bench-top rocker in a water bath at 37°C. 
Paclitaxel release studies were performed by collecting the samples via 
centrifugation at 1000g for five minutes of the entire release medium – the supernatant 
was removed, mixed with 5 ml dichloromethane, shaken for 30 seconds to facilitate drug 
extraction, permitted to settle for 30 minutes for phase separation and the paclitaxel-rich 
oil phase removed for evaluation via UV absorption at 232 nm. Pelleted particles were 
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resuspended in PBS and returned to the water bath. Release studies were done at least in 
triplicate.   
6-carboxyfluorescein release studies were performed by collecting 200 µl samples 
from the release medium at desired time points. Removal of the microparticles was 
achieved by centrifugation at 8000 rpm for five minutes. Three samples of 50 µl of the 
dye-containing supernatant were gathered and placed in a 96 well plate for measurement 
with a fluorescence microplate reader with comparison against a calibration curve with 
excitation and emission wavelengths of 492/517 nm. Pelleted particles were discarded 
(not replaced). Controls consisted of unloaded PLGA particles in the same media at the 
same concentration as well as free 6-CF dissolved in the same media at the same total 
weight as loaded in polymer particles. 
Results and Discussion 
Release of paclitaxel from loaded PLGA spheres and spheroids 
The release profile of paclitaxel from loaded PLGA particles was examined in 
order to demonstrate the ability of the oil-in-water emulsion solvent evaporation method 
to fabricate drug carriers. Prolate spheroid particles were fabricated from PLGA polymer 
(polymer A, Table 2.1) at 1.0% w/V PVA and 0.6% w/V tris in the aqueous phase at pH 
8.4. The theoretical drug load of these particles was 5.0% w/w paclitaxel and the 
measured drug load was 2.7% w/w – an encapsulation efficiency of 54%. Fabricated 
spheroid particles had an average aspect ratio of 8.2 and volume of 232 µm
3
.  
Release from paclitaxel-loaded spheroids showed an initial burst release followed 
by diffusion-controlled release over time, similar to release studies reported in literature 
[4-6]. However, paclitaxel release from these spheroids occurred at a faster rate than 
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reported by the literature, likely due to the particle geometry, though it was consistent 
with diffusion controlled release. Figure 5.2 shows the fraction paclitaxel released over 
two weeks and the fractional loss model predicted by Fick’s Second Law fit to the 
experimental data in order to estimate the diffusion constant for the system. The diffusion 
coefficient for paclitaxel released from these particles was estimated to be 2.8∙10-9 cm2/s, 
similar in magnitude to the diffusion coefficient reported in literature for paclitaxel 
released from a PLGA film [7].  
Particle geometry and its impact on the release rate of loaded therapeutics are 
important considerations in the design of suitable drug delivery carriers. Experiments 
were designed to compare the release rates of spheroids and spheres in order to observe 
the impact of particle shape on release rate. Since the release of paclitaxel from loaded 
spheroids proved to be diffusion controlled, this system was useful in evaluating the role 
of particle shape in diffusion release from carriers. The release of paclitaxel from prolate 
spheroids and spheres of the same particle volumes containing the same drug load was 
observed to this end. 
Paclitaxel-loaded PLGA (polymer C, Table 2.1) prolate spheroids were fabricated 
with an aqueous phase containing 1.0% w/V PVA and 0.6% w/V tris at aqueous phase 
pH 8.4. Fabricated spheroids contained an average drug load of 2.9% w/w (58% 
encapsulation efficiency), had an average particle volume of 196 µm
3
 and an average 
aspect ratio of 9.6. Paclitaxel-loaded PLGA spheres were manufactured from the same 
polymer and in an aqueous phase containing 1.0% w/V PVA and 0.0% w/V tris at 
aqueous phase pH 8.4. The stir rate was decreased from the base formulation to 1600 rpm 
in order to create spheres and spheroids of equivalent volume. Manufactured spheres 
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contained an average drug load of 2.8% w/w (56% encapsulation efficiency) and an 
average diameter of 7.1 µm (187 µm
3
). In vitro release studies were performed in 10 mM 
DPBS at pH 7.4 and 37°C to simulate in vivo conditions.  
Figure 5.3 shows the release of paclitaxel from loaded spheres and spheroids over 
time. The release profile showed a fast burst release over the first day followed by 
diffusion-controlled release over approximately one month. As expected, particle 
geometry impacts the release rate of loaded paclitaxel from these particles; prolate 
spheroid particles show faster release of paclitaxel than spheres of similar volume and 
drug load due to their shortened diffusion path and larger surface area. The effect particle 
shape has on drug release rates is important to consider in the design of these particles as 
a therapeutic treatment [8]. The faster release from stretched, non-spherical particles may 
be more appropriate in situations requiring higher dosages of therapeutic. Alternatively, 
the mass of injected particles may need to be decreased per dose and the dosing 
frequency increased when utilizing spheroids in place of spheres. 
Release of 6-carboxyfluorescein from loaded PLGA spheres and spheroids 
Imaging vectors have the potential to help identify cardiovascular and other 
inflammatory diseases, providing information vital to the following treatment of those 
diseases [9-11]. Additionally, drug delivery particles with imaging capabilities may be 
useful in tracking the placement of the carriers at the site of interest and the 
biodistribution of the particles [12]. The fluorescent dye 6-carboxyfluorescein was loaded 
into prolate spheroids and spheres of similar volumes made from PLGA polymer for use 
as imaging vectors. Its release from those carriers over time is of interest not only as a 
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model drug release but also because release lessens the intensity of signal from the 
particles, decreasing their usefulness for imaging.  
6-CF-loaded PLGA (polymer A, Table 2.1) spheroids were fabricated from an 
aqueous phase containing 1.0% w/V PVA with 0.6% w/V tris at pH 8.4. Fabricated 
spheroids contained an average drug load of 0.39% w/w (39% encapsulation efficiency), 
average particle volume of 160 µm
3
 and average aspect ratio 11.7. 6-CF-loaded spheres 
were made in the presence of an aqueous phase consisting of 1.0% w/V PVA and 0.0% 
w/V tris at aqueous phase pH 8.4. Fabricated spheres had an average drug load of 0.35% 
w/w (3% encapsulation efficiency) with an average particle diameter of 6.7 µm and 
particle volume 165 µm
3
. In vitro release studies were performed in 10 mM DPBS at pH 
7.4 and 37°C similar to in vivo conditions. 
Release of 6-CF previously recorded in literature was from nanospheres on the 
order of 200 nm [13]. 6-CF in that study was released in a matter of hours rather than 
weeks as seen with paclitaxel, likely due to the small particle volume. Figure 5.4 shows 
the release of 6-CF from loaded rods and spheres of equivalent volumes. Dye release 
from loaded spheroids showed fast release compared with paclitaxel release as expected 
due to the increased solubility of 6-CF in the aqueous release media. Twenty percent of 
loaded dye was released within 5 hours, 80% within 2 days and all dye was released 
within 2 weeks from dye-loaded rods. While this was significantly slower than reported 
in literature, the fabricated particles were significantly larger in volume and therefore 
released their load much more slowly due to the greater diffusion path. The release of 6-
CF from loaded spheres was dramatically different than release from rods – dye release 
from spheres showed a burst release of almost 20% followed by little release over the 
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first two weeks before the release rate increased. Spheres released almost all of the 
loaded 6-CF over a five week period, more than twice as long as full release from rods. 
Dye release from spheres shows a degradation-dependent release; initial release was slow 
and steady as the pore size was too small for quick diffusion. Over time, the pore size 
was increased through degradation and particle swelling, thus releasing loaded dye 
molecules.  
The wide difference in release rates between spheroids and spheres is due to the 
effect of tris on the loading of 6-CF during fabrication. Rods were fabricated in the 
presence of tris in the aqueous phase whereas spheres had no tris in the aqueous phase. 6-
CF is a water-soluble dye at neutral and basic pH due to the charge present on its 
functional groups above neutral pH; the pK for the alcohol group is 6.3 and the pK is 4.5 
for its terminal carboxyl group [14], causing the partition coefficient to drastically 
decrease at pH above 6.3. Ethanol was required as a co-solvent to dissolve the dye in the 
oil phase. Upon emulsification, the ethanol diffuses into the water phase faster than DCM 
due to its higher water solubility. The water soluble dye has a low partition coefficient at 
basic pH, causing it to diffuse rapidly into the water phase as well [14, 15]. Particles 
fabricated in the absence of tris (spheres) showed very low loading efficiencies. When 
tris was in the aqueous phase, it lowered the interfacial tension, increasing the diffusion 
of DCM into the aqueous phase and of water (containing tris) into the oil phase. When 
tris contacts 6-CF within the oil phase, it is protonated and makes the dye anionic. This 
causes precipitation of the dye within the oil phase, increasing the encapsulation 
efficiency. Additionally, faster diffusion rates across the interface results in significantly 
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larger pore sizes. In the absence of tris, diffusion was significantly slower, causing small 
pore sizes and requiring particle degradation before 6-CF release could be achieved.  
Summary 
The in vitro release of paclitaxel and 6-carboxyfluorescein from loaded PLGA 
spheroids and spheres was examined in PBS at pH 7.4 and 37°C. Paclitaxel was loaded as 
a model hydrophobic chemical drug and its release from PLGA particles was diffusion-
controlled, displaying a small burst release. Loaded paclitaxel released faster from 
spheroids than spheres, as predicted by Fick’s Second Law, and particles of both 
geometries released their load over about a month. 6-carboxyfluorescein was loaded as 
dye permitting the use of loaded particles as contrast agents. Release from spheroids 
showed a rapid, diffusion-based release over a few days. This is likely due to the 
concentration of 6-CF near the surface of the particle during loading in the presence of 
tris base. Release from loaded spheres showed an initial burst release followed by 
minimal release for two weeks at which point it released over three weeks, indicating 
degradation-controlled release. 
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Figure 5.1: Diffusion-controlled release model based on Fick’s Second Law from 
spheres and spheroids of different aspect ratios. Spheres and spheroids have equivalent 
volumes. 
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Figure 5.2: Paclitaxel release from PLGA (polymer A, Table 2.1) prolate spheroids 
fabricated from  the oil-in-water emulsion solvent evaporation technique compared to a 
diffusion-controlled release model. The diffusion coefficient of paclitaxel in PLGA was 
calculated to be 2.8∙10-9 cm2/s. 
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Figure 5.3: Release of paclitaxel from PLGA (polymer C, Table 2.1) spheres and prolate 
spheroids of the same volume and drug load manufactured using the oil-in-water 
emulsion solvent evaporation method.  
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Figure 5.4: Release of 6-carboxyfluorescein from PLGA (polymer A, Table 2.1) spheres 
and prolate spheroids of the same volume and drug load manufactured using the oil-in-
water emulsion solvent evaporation method. 
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CHAPTER VI 
Major contributions and future work 
Major contributions 
This work describes a novel fabrication of non-spherical particles from 
biodegradable PLGA polymer for drug delivery applications utilizing oil-in-water and 
water-in-oil-in-water emulsion solvent evaporation techniques. It was shown that the size 
and shape (aspect ratio) of these fabricated prolate spheroids can be controlled by careful 
manipulation of process parameters in the aqueous and oil phases as well as the physical 
setup of the system. The data showed that a high aqueous phase viscosity, a basic 
aqueous phase pH, a water-soluble co-solvent and hydrophilic end groups on the polymer 
chain are all conditions that promote formation of spheroidal particles. 
Spheroids were successfully fabricated utilizing these emulsion techniques loaded 
with a wide range of therapeutics including hydrophobic (paclitaxel and lovastatin), 
water-soluble (6-carboxyfluorescein), nanoparticles (cadmium sulfide) and protein 
(bovine serum albumin) model drugs as proof of concept for their potential applications 
in drug delivery. Furthermore, spheroids loaded with contrast agents including 6-
carboxyfluorescein and cadmium sulfide fluorescent nanoparticles show the flexibility of 
these spheroids for use in imaging applications. Loaded particles showed the same
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variation in size and shape with varied system parameters as observed with unloaded 
particles. The impact of process parameters on encapsulation efficiencies was not 
consistent between loaded therapeutics – each loaded drug responded differently 
depending on its characteristics. Paclitaxel displayed loading efficiencies consistent with 
hydrophobic drugs loaded into spheres described in literature while 6-carboxyfluorescein 
encapsulation efficiency depended largely on the presence of tris base in the aqueous 
phase, changing the dye solubility in dichloromethane and causing the precipitation of the 
dye in the oil phase.  
Bovine serum albumin, a model protein, required the added complexity in 
fabrication of a primary emulsion entrapping the BSA within an inner water phase 
contained in the oil droplets. The size and shape of particles loaded with BSA fabricated 
with the W/O/W ESE system followed the same trends as unloaded and loaded particles 
fabricated with a single emulsion. The dependence of encapsulation efficiency of BSA in 
the double emulsion fabrication was different than that observed with drugs loaded in a 
single emulsion fabrication. In the case of BSA loading, parameters that stabilized the 
inner water phase (basic pH, high surfactant concentration) increased the loading 
efficiency due to decreased merging of inner and outer water phases. 
Drug release was examined from particles loaded with paclitaxel or 6-
carboxyfluorescein. Release of the hydrophobic drug paclitaxel from PLGA particles was 
diffusion-controlled, showing a small burst release and releasing loaded drug over 
approximately one month from both spheroids and spheres of the same volume and drug 
load. Particle geometry influenced the release rate of loaded paclitaxel; spheroids 
released their cargo faster than their spherical counterparts due to the larger surface area 
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of prolate spheroids as predicted by the diffusion drug release model. Drug release from 
6-carboxyfluorescein-loaded spheroids occured rapidly over the course of a few days, 
clearly displaying diffusion-controlled release likely due to the concentration of 6-CF 
near the surface of the particle as a result of the presence of tris base during fabrication. 
6-CF showed a degradation-dependent release from loaded spheres, however. Release 
from spheres showed an initial burst release of approximately 20% of loaded 6-CF 
followed by no release from two weeks. After sufficient degradation, release began again 
at the end of two weeks and continued until all dye was released after a total of five 
weeks. 
Overall, the O/W and W/O/W emulsion solvent evaporation techniques for 
fabricating prolate spheroids are advantageous over other methods currently described in 
the literature in their simplicity in setup, high particle yield and adaptability to various 
biodegradable polymers and therapeutics. There is evidence in the literature that 
spheroidal particles are potentially advantageous over spherical particles for in vivo drug 
delivery and imaging. The simple fabrication technique described in this work allows 
investigators quick and inexpensive access to a high yield of these particles and thus 
rapidly advance their potential for in vivo application.  
Predicting droplet deformation and breakup 
Drop deformation and breakup in shear flows is governed by the viscous and 
interfacial forces present in the system. Mechanically-mixed emulsions of immiscible 
phases lead to the formation of a population of drops of the dispersed phase within the 
continuous phase. In this fabrication technique, the oil phase consisting of PLGA 
polymer and therapeutic dissolved in dichloromethane makes up the dispersed phase in 
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order to cause the precipitation of polymer particles with the removal of the solvent 
dichloromethane through diffusion into the continuous aqueous phase. Upon injection of 
the oil phase into the aqueous phase, the shear force imparted by the impeller drives the 
breakup of the oil phase into droplets that quickly reach an equilibrium average drop size. 
The drop shape is characterized by the viscosity ratio and capillary number (Eqns. 
2.1 & 2.2) and determined by the viscous and interfacial forces [1]. Deformation tends to 
form prolate spheroid shapes with the major axis oriented at a characteristic angle θ with 
respect to the direction of shear [2]. The system parameters affecting the viscous and 
interfacial forces include the shear rate imposed by the impeller, the viscosities of the two 
phases and the interfacial tension between the phases. Ideally, a predictive model of 
droplet deformation and breakup is achievable given perfect knowledge of these system 
parameters. Such a model would permit useful predictions about the physical 
characteristics of particles formed at any given fabrication conditions. For droplet 
deformations without breakup, deformation in simple shear flows has been shown to be 
weakly dependent on the viscosity ratio and proportional to the capillary number for low 
viscosity ratios: 
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where L is the major axis length and B the minor axis length [3, 4]. Subsequent 
refinements have altered this depending on the relevant flow pattern, but for low viscosity 
ratios this generally holds true [5, 6]. However, most theoretical models and experiments 
do not simultaneously deal with droplet deformation and breakup due to the complexity 
of such systems. 
Unfortunately, the dynamic conditions that exist during the fabrication preclude 
perfect predictions. The culprits here are the changing viscous shear forces due to the 
breakup and coalescence of the drops as well as obtaining accurate interfacial tension 
measurements that describe the rapidly evolving environment during particle 
solidification in the solvent removal stage. Droplet breakup due to shear forces 
overcoming interfacial tension forces results in smaller shear forces on the smaller 
resulting drop, causing smaller deformation. This was observed experimentally with 
increasing aqueous phase viscosity achieved through the variation of polyvinyl alcohol 
concentration in the water phase. Increasing viscosity initially increased deformation 
while simultaneously decreasing particle volume (Figure 2.7), yet further increase in 
viscosity decreased deformation as interfacial forces dominated shearing forces for the 
small drops. Additionally, the droplet size decreases during this emulsion as the solvent 
dichloromethane diffuses into the aqueous phase, changing the capillary number and 
subsequent deformation over time. The drop will no longer change shape once a 
sufficient fraction of the solvent has left the droplet, but the prediction of when exactly 
deformation changes cease is complex. 
Accurate measurements of interfacial tension, particularly dynamic measurements 
during the solvent evaporation phase, are difficult to obtain. Interfacial tension 
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measurements were made using a Du Noüy ring force tensiometer between the aqueous 
and oil phases prior to emulsification. While this method yielded results for concentration 
changes in the aqueous phase (Figure 2.1), it was insensitive to interfacial tension 
changes caused by several polymer properties such as end group, molecular weight and 
co-monomer ratio. Interfacial tension in the emulsion system changes with droplet 
formation and shape changes, particularly with the presence of surfactants, causing these 
measurements to not accurately describe the actual environment [5, 6]. The dynamic 
droplet size and interfacial tension make it difficult to accurately calculate the capillary 
number and therefore makes predicting the deformation (aspect ratio) and volume of 
resultant, hardened particles complicated. What can be observed is the general trend of 
deformation with changing viscosities, shear and interfacial tension as observed above 
and in Chapter II. 
Future work 
The described research introduces a new method for the fabrication of 
biodegradable, non-spherical microparticles for potential application in drug delivery. 
The challenges of drug carrier design are to account for several factors including particle 
material, size and shape in order to provide effective targeted delivery through efficient 
encapsulation of therapeutic, localization to the target site and release of the therapeutic 
[7]. Efficient targeted delivery requires localizing to the target site while avoiding 
clearance by the immune system by maneuvering through the bloodstream to the target. 
There are advantages and disadvantages to differently sized particles in this regard; 
nanoparticles are attractive as they have prolonged circulation and are unlikely to occlude 
small blood vessels. However, nanoparticles may not effectively marginate to the 
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vascular wall in medium or large vessels while microspheres may offer much improved 
margination in these vessels [7-9]. Yet microspheres are readily cleared and may occlude 
the capillaries; PEGylation of these particles can further increase circulation time, but a 
change to non-spherical shapes may be optimum for drug delivery and imaging 
applications [10]. The prolate spheroid particles fabricated with this method may provide 
better efficacy as imaging and drug delivery carriers. 
Studies evaluating these drug delivery carriers for the in vitro and in vivo efficacy 
need to be performed to confirm possible advantages of the non-spherical carriers. In 
vitro flow assays quantifying adhesion to inflamed endothelial cells from blood flow for 
different particle geometries may confirm this hypothesis and identify the particle volume 
and aspect ratios optimal for each flow type, whether slow flows present in small vessels 
or larger, pulsatile flows typical of medium-to-large arteries. Such studies have been 
performed for spherical particles of different sizes binding to inflamed endothelial cells 
[8, 9], but need to be performed for prolate spheroids. Unloaded PLGA prolate spheroids 
fabricated from the oil-in-water emulsion solvent evaporation method may be utilized to 
this end. 
Even though in vitro assays may confirm that spheroids offer advantages in 
binding efficiency and identify size and aspect ratios that work best, they cannot recreate 
perfectly the in vivo environment nor guarantee the same performance there. The ability 
of drug carriers to the reach their target in vivo depends on the blood pharmacokinetics. 
Blood clearance is a function of particle concentration, volume, shape and surface 
characteristics. The blood clearance and biodistribution of particles injected into animal 
models, such as mice, needs to be examined further to determine any potential benefit to 
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non-spherical particles for drug delivery. Of particular interest for prolate spheroids is an 
investigation of the capillaries to determine if elongated particles are entrapped and 
occlude these small vessels. Pharmacokinetic parameters such as blood/deposition half-
life, distribution volume and clearance will help determine the ultimate fate of injected 
particles.  
Analysis of the ability of non-spherical PLGA particles to target inflamed vessels 
in atherosclerotic animal models and a determination which particle sizes and aspect 
ratios should be investigated. Fluorescent imaging in whole blood and tissue samples 
may permit for the evaluation of binding efficiency; the fluorescent 6-CF and CdS PLGA 
prolate spheroids fabricated in this work provide the particles needed for such a study. 
Although human in vivo assays would be preferred, human subjects are not feasible at 
this stage of this research and even though mice models provide more complexity, 
significant differences exist between mice and human models. Animal models are 
insufficient to identify the best imaging and carriers in humans; differences in vessel 
sizes and blood flow patterns, including shear stresses and red blood cell size and shape, 
necessitate eventual human trials [11]. However, in vivo mice models provide the 
complex hydrodynamic blood flows that are absent from simple laminar or pulsatile 
flows inherent in in vitro assays. Once optimal carriers and target ligands are designed, 
effective targeted imaging and drug delivery may provide safe and effective treatment of 
cardiovascular diseases. This novel fabrication method provides access to non-spherical 
particles made from biodegradable polymers for the design of optimal drug delivery 
carriers. 
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